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1.INTRODUCTION 
 
1.1. Oral drug delivery system:       
(Banker G.S and Rhodes C.T., 2009; Chein Y.W., 2002) 
 An ideal drug delivery system should aid in the optimization of drug therapy 
by delivering an appropriate amount to the intended site and at a desired rate. Hence, 
the DDS should deliver the drug at a rate dictated by the needs of the body over the 
period of treatment. An oral drug delivery system providing a uniform drug delivery 
can only partly satisfy therapeutic and biopharmaceutical needs, as it doesn’t take in 
to account the site specific absorption rates within the gastrointestinal tract (GIT). 
Therefore there is a need of developing drug delivery system that release the drug at 
the right time, at the specific site and with the desired rate. 
1.2. Drawbacks associated with conventional dosage forms:   
(Brahmankar D.M. and Jaiswal S.B., 2009; http://www.pharmainfo.net) 
       1. A drug with short biological half life which needs a close succession 
administration is required, so it may increase the missing of dosage form leads to Poor 
patient compliance.  
       2. The uncontrollable fluctuation of drug level may leads to either below 
effective range or over the effective range. 
       3. Plasma concentration verses time profile of dosage form and it’s difficult to 
achieve the steady state active drug level.  
        4. The rise and fall of drug levels it may give to accumulation of adverse 
effects especially for a drug having less therapeutic index.  
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Figure 1.1: Plasma drug concentration profiles for conventional tablet    
 formulation, a sustained release formulation and a zero order   
 controlled release formulation. 
1.3. Sustained release drug delivery system:  
 (Banker G.S. and Rhodes C.T., 2009; Shargel L. and Andrew B.C.Y., 2005; 
Aulton M.E., 2007; Ansel H.C., 2009; Brahmankar D.M. and Jaiswal S.B., 2009)  
 The main destination of any drug delivery system is to furnish a contributing 
to quantity of a drug to a suitable region in the body and that the required drug 
concentration can be attained promptly and then being maintained. The drug delivery 
system should distribute a drug at a rate dictated by the require of the body for 
particular length of time. Regarding this existing points there are two important 
aspects to delivery system, said as, spatial placement and temporal delivery. Spatial 
placement connected to targeting a drug to particular organ, tissues, cells, or even sub 
cellular area; whereas temporal delivery system deals to controlling the rate of dosage 
form to the targeting region. 
            Sustained release tablets and capsules are mostly taken only once or twice 
daily, compared with immediate release tablet form that may have to take 3 or 4 times 
Ibuprofen sustained Release Tablets                             Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 3 
a day to attain the same required drug to produce the effect. Typically,  the sustained 
release dosage form to furnish at once release the active component that give the what 
we are desired for cure of disease, followed by remaining quantity of drug should be  
release and maintained the therapeutic effect  over a predetermined length time or 
prolonged period. The sustaining of drug plasma levels furnish by sustained release 
dose often times to eliminate the require for night dose administration, which suitable 
not only the patient but the care given as well. 
            The bulk of research can be focusing toward oral dosages that improve the 
temporal aspect of drug delivery. This approach is a continuously developing in the 
pharmaceutical industry for sustained release oral drug delivery system.  
 The sustained release system for oral use of administration are mostly solid 
and based on dissolution, diffusion or a combination of both, erosion mechanisms, in 
the power to directing the drug release. A delivery system containing hydrophilic and 
hydrophobic polymers and waxes are mixed with active component to furnish drug 
action for a prolonged length of time.  
 The concept of modified release dosage products was previously used to 
describe various types of oral extended release dosage forms, including sustained 
release, sustained action, prolonged action, slow release, long action and retarded 
release.  
 The USP/NF associated with several types of modified-release dosage forms, 
1. Extended release dosage forms. (e.g. sustained release dosage forms, controlled 
release dosage forms) 
2. Delayed release dosage forms (e.g. enteric coated tablets) 
3. Targeted release dosage forms.  
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The United States Pharmacopoeia has been in the term extended release 
and the British Pharmacopoeia has been the term slow release. United States Food 
and Drug Administration has been in the term prolonged release. However the 
review of literature indicates that widely used in terms today are sustained release and 
controlled release. 
Modified release dosage forms: It is a dosage form are defined by the USP as those 
whose drug release characteristics of time course or location are chosen to accomplish 
therapeutic or convenience objective not offered by conventional or immediate release 
form. Also this dosage form which is sufficiently controlled to provide periods of 
prolonged therapeutic action following each administration of a single dose.  
Extended release dosage form: It is a dosage forms release drug slowly, so that 
plasma concentration is maintained at a therapeutic level for a period of time. 
Delayed release dosage form: It is a dosage form which indicates that the drug is not 
being released immediately following administration but at a later time, e.g. enteric 
coated tablets. 
Prolonged release dosage form: It is a dosage form which indicates that the drug is 
provided for absorption over a longer period of time than from a conventional dosage 
form. 
Sustained release dosage form: It is a dosage form which indicates an initial release 
of drug sufficient to provide a therapeutic amount dose soon after administration, and 
then a gradual release over an extended period of time. 
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1.3.1.
 Advantages of sustained release drug delivery system:  
(Banker G.S and Rhodes C.T., 2009; Chein Y.W., 2002) 
       Some advantages are as follows 
1. Reduction in dosing frequency. 
2. Reduced fluctuation in circulating drug levels. 
3. Increased patient convenience and compliance. 
4. Avoidance of night time dosing. 
5. More uniform effect. 
6. Maximum utilization of drug. 
7. Reduction in GI irritation and other side effects. 
8. Reduction in health care cost through improved therapy. 
9. Improve bioavailability of some drugs. 
1.3.2. Disadvantages of sustained release drug delivery system:  
(Banker G.S. and Rhodes C.T., 2009; Chein Y.W., 2002) 
1. Decreased systemic availability in comparison to immediate release 
conventional dosage form. This may be due to  
 Incomplete release   
 Increased first-pass metabolism, increased instability 
 Site specific absorption, pH dependant solubility, etc. 
2. Poor in vitro-in vivo correlation. 
3. Possibility of dose dumping. 
4. Retrival of drug is difficult in case of toxicity, poisoning, or hypersensitivity 
reactions. 
5. Higher cost of formulation. 
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1.3.3. Rationale of sustained release drug delivery system: 
                                                     (http://www.pharmainfo.net; Chein Y.W., 2002) 
 The basic rationale for sustained drug delivery is to alter the pharmacokinetic 
and pharmacodynamics of pharmacologically active moieties by using novel drug 
delivery systems or by modifying the molecular structure and/or physiological 
parameters inherent in a selected route of administration. It is desirable that the 
duration of drug action become more to design properly. Rate controlled dosage form, 
and less, or not at all, a property of the drug molecules inherent kinetic properties.  
As mentioned earlier, primary objectives of controlled drug delivery are to 
ensure safety and to improve efficiency of drugs as well as patient compliance. This 
achieved by better control of plasma drug levels and frequent dosing. For 
conventional dosage forms, only the dose and dosing interval can vary and, for each 
drug, there exists a therapeutic window of plasma concentration, below which 
therapeutic effect is insufficient, and above which toxic side effects are elicited. This 
is often defined as the ratio of median lethal dose (LD 50) to median effective dose 
(ED50).  
1.3.3. Design of sustained release drug delivery system:  
 (Jithan A., 2007; Ansel H.C., 2009; Shargel L. and Andrew B.C.Y., 2005) 
  Practically there are two modern methods are mostly used by pharmaceutical 
manufacturing scientist in the designing of dosage form for sustained release tablet. In 
that the first approach method are mainly involved to modifying of properties like 
physical and chemical nature of the drug and the second method is how to modify the 
release of drug from the prepared dosage form. Physical and chemical characteristic 
of the active component can be developed by formatting complex type, drug and 
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adsorbate formulation, or prodrug synthesis. The conversion of inactive form to active 
nature process is mostly attempted and investigated. The second method is used in the 
formulation development of sustained release system. This is popular method because 
it’s inherent advantage. The advantage of this method in the design of dosage form is 
independent. The final formulation form could be in a liquid suspension form, a 
capsule or a tablet. 
 Generally some important criteria could be considering in the formulation of a 
sustained release dosage form. Not all the drug ideal characteristic. Drugs which 
shown neither very slow or nor very fast rate of absorption and excretion. Drugs with 
very short half life that is less than 2 hours are poor candidates for sustained release 
because large quantities of drug required for such a formulation.  
 The drug should be absorbed in the gastro intestinal region. Drug 
manufacturing in sustained release tablet it have been good solubility in the intestinal 
and gastric fluid. They are administered in relatively small doses, drug with large 
single doses frequently are not suitable for sustained release. Sustained release dosage 
form mainly used in case of chronic condition than the acute condition. If the 
medicine need for acute condition at that we have to change the dose adjustment by 
physician alike that is given in sustained release form. Drug should have solubility 
and permeability properties. Drug with less protein binding properties. Drug should 
not produce local irritation. 
 
 
 
 
Ibuprofen sustained Release Tablets                             Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 8 
1.4. Drug properties relevant to sustained release formulation:    
 (Chein Y.W., 2002; http://www.pharmainfo.net) 
The formulation of sustained release drug delivery systems, consider the some 
criteria such as the route of administration, type of  drug delivery system, what 
disease to be treated, the patient, the duration  of treatment  and the characteristic  of 
the drug those above mentioned factor should be considered. The pharmaceutical 
interest to research scientist for designing of the delivery system the following 
properties could be considered in the development of dosage form. These properties 
can be classified as follows. 
  A) Physicochemical properties 
B) Biological properties 
These properties having the greater importance in the design of the drug in the 
delivery system and in the body. But there is no distinction between these two 
categories because the biological properties of a drug as like a function of its 
physicochemical properties. By definition, physicochemical properties of drug that can 
be determined from in vitro study and biological properties will be those that result 
from Pharmacokinetic studies such as absorption, distribution, metabolism and 
excretion of a drug and those resulting from pharmacological experimental study. 
A. Physicochemical factors influencing oral sustained-release dosage form 
design:  
a) Dose size: 
For orally administered systems, there is an upper limit to the bulk size of the 
dose to be administered. In general, a single dose of 0.5- 1.0g is considered maximal 
for a conventional dosage form. This also holds for sustained release dosage form. 
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Compounds that require large dosing size can sometimes be given in multiple 
amounts or formulated into liquid systems. Another consideration is the margin of 
safety involved in administration of large amount of a drug with a narrow therapeutic 
range. 
b) Ionization, pka and aqueous solubility: 
Most drugs are weak acids or bases. Since the unchanged form of a drug 
preferentially permeates across lipid membranes, it is important to note the 
relationship between the pka of the compound and the absorptive environment. 
Presenting the drug in an unchanged form is advantageous for drug permeation. 
Unfortunately, the situation is made more complex by the fact that the drug’s aqueous 
solubility will generally be decreased by conversion to unchanged form. Delivery 
systems that are dependent on diffusion or dissolution will likewise be dependent on 
the solubility of the drug in aqueous media. These dosage forms must function in an 
environment of changing pH, the stomach being acidic and the small intestine more 
neutral, the effect of pH on the release process must be defined. Compounds with very 
low solubility (<0.01mg/ml) are inherently sustained, since their release over the time 
course of a dosage form in the GI tract will be limited by dissolution of the drug. So it 
is obvious that the solubility of the compound will be poor choices for slightly soluble 
drugs, since the driving force for diffusion, which is the drug’s concentration in 
solution, will be low. 
c) Partition Coefficient: 
When a drug is administered to the GI tract, it must cross a variety of 
biological membranes to produce a therapeutic effect in another area of the body. It is 
common to consider that these membranes are lipidic; therefore the partition 
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coefficient of oil-soluble drugs becomes important in determining the effectiveness of 
membrane barrier penetration. Compounds which are lipophilic in nature having high 
partition coefficient are poorly aqueous soluble and it retain in the lipophilic tissue for 
the longer time. In case of compounds with very low partition coefficient, it is very 
difficult for them to penetrate the membrane, resulting in poor bioavailability. 
Furthermore, partitioning effects apply equally to diffusion through polymer 
membranes. The choice of diffusion-limiting membranes must largely depend on the 
partitioning characteristics of the drug. 
d) Drug Stability: 
Orally administered drugs can be subject to both acid-base hydrolysis and 
enzymatic degradation. Degradation will proceed at a reduced rate for drugs in solid 
state; therefore, this is the preferred composition of delivery for problem cases. For 
the dosage form that are unstable in stomach, systems that prolong delivery over 
entire course of transit in the GI tract are beneficial; this is also true for systems that 
delay release until the dosage form reaches the small intestine. Compounds that are 
unstable in small intestine may demonstrate decreased bioavailability when 
administered from a sustaining dosage form. This is because more drugs is delivered 
in the small intestine and, hence, is subject to degradation. Propentheline and 
probanthine are representative example of such drug. 
e) Protein binding: 
 Its properties the drugs are binding to blood protein. The drug-Protein 
complex it can act as a depot for drug molecule and to release a drug for prolonged 
period and leads to exhibit a highly binding to plasma. The attractive forces is mainly 
applicable for binding are vanderwaals forces, hydrogen bonding and electrostatic 
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forces. If a drug molecule having hydrophobic in nature its can also increasing the 
binding capacity. Drugs binding to mucin it may increase absorption. e.g. quaternary 
ammonium compounds bound to mucin in the gastro intestinal tract. 
B. Biological factors influencing oral sustained-release dosage form design: 
a) Biological half life: 
The usual goal of an oral SR product is to maintain therapeutic blood levels 
over an extended period of time. To achieve this, drug must enter the circulation at 
approximately the same rate at which it is eliminated. The elimination rate is 
quantitatively described by the half-life (t1/2). Each drug has its own characteristic 
elimination rate, which is the sum of all elimination processes, including metabolism, 
urinary excretion and all over processes that permanently remove drug from the blood 
stream. Therapeutic compounds with short half-life are generally are excellent 
candidate for SR formulation, as this can reduce dosing frequency. In general, drugs 
with halflives shorter than 2 hours such as furosemide or levodopa are poor 
candidates for SR preparation. Compounds with long half-lives, more than 8 hours are 
also generally not used in sustaining form, since their effect is already sustained. 
Digoxin and phenytoin are the examples. 
b) Absorption: 
Since the purpose of forming a SR product is to place control on the delivery 
system, it is necessary that the rate of release is much slower than the rate of 
absorption. If we assume that the transit time of most drugs in the absorptive areas of 
the GI tract is about 8-12 hours, the maximum half-life for absorption should be 
approximately 3-4 hours; otherwise, the device will pass out of the potential 
absorptive regions before drug release is complete. Thus corresponds to a minimum 
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apparent absorption rate constant of 0.17-0.23h-1 to give 80-95% over this time 
period. Hence, it assumes that the absorption of the drug should occur at a relatively 
uniform rate over the entire length of small intestine. For many compounds this is not 
true. If a drug is absorbed by active transport or transport is limited to a specific 
region of intestine, SR preparation may be disadvantageous to absorption. One 
method to provide sustaining mechanisms of delivery for compounds try to maintain 
them within the stomach. This allows slow release of the drug, which then travels to 
the absorptive site. These methods have been developed as a consequence of the 
observation that co-administration results in sustaining effect. One such attempt is to 
formulate low density pellet or capsule. Another approach is that of bioadhesive 
materials. 
c) Metabolism: 
Drugs those are significantly metabolized before absorption, either in the 
lumen or the tissue of the intestine, can show decreased bioavailability from slower-
releasing dosage form.  
Hence criteria for the drug to be used for formulating Sustained-Release dosage form 
is,  
♦ Drug should have low half-life(<5 hrs) 
♦ Drug should be freely soluble in water 
♦  Drug should have larger therapeutic window 
♦ Drug should be absorbed throughout the GIT. 
Even a drug that is poorly water soluble can be formulated in SR dosage form. For the 
same, the solubility of the drug should be increased by the suitable system and later 
on that is formulated in the SR dosage form. But during this the crystallization of the 
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drug, that is taking place as the drug is entering in the systemic circulation, should be 
prevented and one should be cautious for the prevention of the same. 
d) Distribution: 
The distribution of active ingredient into body tissues and extra vascular 
spaces in the body is an important parameter for drug elimination kinetics model. 
Some parameters are using to give idea about distribution of drug. Apparent volume 
of distribution of active component is high it will influence the elimination of dosage 
form and not suitable for making sustained release tablet. The term apparent volume 
of distribution of a drug is mostly used to explain the distribution, including bound to 
the body system. The total apartment volume of distribution for a drug at steady state 
will be calculated by given equation. 
 Vdss = [(K12 + K21) / K21] VP 
Where, 
Vdss =  Apparent volume of distribution at study state level 
K12 =  Drug from central to peripheral compartment 
K21 =  Drug from peripheral to central compartment 
VP =  Volume of central compartment 
e) Side effects: 
 The incidence of side effect of a drug is depends on its therapeutic 
concentration level in blood. It can be remedy by the drug concentration level is 
controlled at which timing that drug exists in blood after administration. Toxic effect 
of a drug is expected above the maximum effective range level and fall in the 
therapeutic effect if a drug below the level of minimum effective range. So the above 
problem we can solve by making sustained release preparation. 
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f) Margin of safety: 
 Therapeutic index of a drug is very important for either sustained or controlled 
release delivery system. Its value only desired the margin of safety. Therapeutic index 
value it has been longer means excellent for preparation of sustained release tablet. 
Narrow therapeutic index of some drug precise to release the active content in 
therapeutic safe and effective range. Some drug like cardiac glycosides that 
therapeutic index value is very small, so it’s not used for sustained release delivery 
system.   
              Therapeutic index = TD50  ∕ ED50 
                    Where, 
                             TD50   - Median toxic dose 
                             ED50    - Median effective dose 
1.5. Design and fabrication of oral systems:            
 (Brahmankar D.M. and Jaiswal S.B., 2009; Robinson J.R. and Lee V.H.L., 2009; 
Chein Y W., 2002) 
  The majority of oral controlled release systems rely on dissolution, diffusion or 
a combination of both mechanisms, to generate slow release of drugs into the 
gastrointestinal milieu. The following techniques are employed in the design and 
fabrication of oral sustained release dosage forms.  
       1. Dissolution controlled release  
 Encapsulation dissolution control 
 Matrix dissolution control  
 
       2. Diffusion controlled release  
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• Reservoir devices 
• Matrix  devices 
3.  Diffusion and dissolution controlled systems 
4.  Ion-exchange resins  
5.  pH - independent formulations 
6. Osmotically controlled release 
7. Altered density formulations  
1.5.1. Dissolution controlled Systems: 
 Drug with a slow dissolution rate will demonstrate sustaining properties, since 
the release of the drug will be limited by rate of dissolution. This being the case, SR 
preparations of drugs could be made by decreasing their dissolution rate. This 
includes preparing appropriate salts or derivatives, coating the drug with a slowly 
dissolving material, or incorporating it into a tablet with a slowly dissolving carrier.
 The dissolution process at steady state, is described by Noyes-Whitney 
equation, 
dc/dt = KDA(Cs-C) = D/h A(Cs-C) 
Where,  
dc/dt  = Dissolution rate 
KD = Diffusion co-efficient 
A         = surface area of the dissolving solid
 
Cs = Saturation solubility of the solid 
C = Concentration of solute in bulk solution 
H = Thickness of diffusion layer 
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Encapsulation dissolution control  
• These methods generally involve coating individual particles of drug 
with a slow dissolving material. The coated particles can be directly 
compressed into tablets as in space tabs or placed in capsules as in 
spansule products. 
• Since the time required for dissolution of the coat is a function of 
thickness and aqueous solubility, sustained action can be obtained by 
employing a narrow or a wide spectrum of coated particles of varying 
thickness respectively. 
Matrix dissolution control  
• Those methods involve compressing the drug with a slowly dissolving 
carrier into a tablet form. Here the rate of drug availability is controlled 
by the rate of penetration of dissolution fluid into the matrix. 
• This in turn can be controlled by porosity of the tablet matrix, the 
presence of hydrophobic additives and   wettability of granule surface. 
 
Figure 1.2: Dissolution controlled matrix system 
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1.5.2. Diffusion controlled systems:                                                                                                 
 Basically diffusion process shows the movement of drug molecules from a 
region of higher concentration to one of lower concentration. Diffusion systems are 
characterized by the release rate being dependent on its diffusion through an inert 
membrane barrier. Usually this barrier is an insoluble polymer. 
Membrane reservoir diffusion controlled 
The core of the drug is encapsulated within a water insoluble polymeric 
material. The drug will partition in to the membrane and diffuse in to the fluid 
surrounding the particle or tablet. Cellulose derivatives are commonly used in the 
reservoir types. 
Ficks first law of diffusion describes the diffusion process 
J= -D dc/dx 
Where, 
 D = diffusion coefficient in area/time 
 dc/ dx = change of concentration ‘c’ with distance ‘x’  
 
Figure 1.3: Schematic representation of reservoir diffusion controlled drug release 
            reservoir 
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Advantages: 
        Zero order delivery is possible; release rate varies with polymer type. 
Disadvantages: 
1. Systems must be physically removed from implant sites. 
2. Difficult to deliver high molecular weight compounds. 
3. Increased cost per dosage unit, potential toxicity if system fails. 
Matrix diffusion controlled: 
It this system a solid drug is dispersed in an insoluble matrix. The rate of drug 
release is controlled by the rate of   diffusion   of drug and not by the rate of solid 
dissolution.  In this model, drug in the outside layer exposed to bath solution is 
dissolved first and then diffuses out of the matrix. The following equation describe the 
rate of release of drug dispersed in an inert matrix system have been derived by 
Higuchi, 
dQ/dt =(DACS/2t)1/2 
where  
‘A’ is the total amount of the drug in the device,  
‘D’ is the diffusion coefficient of the drug in the polymer, ‘Cs’ is the solubility of the 
drug in the polymer,‘t’ is time. 
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Figure 1.4: Release of drug dispersed in an inert matrix system 
Advantages: 
            Easier to produce than reservoir or encapsulated devices, can deliver high 
molecular weight compounds. 
Disadvantages: 
Cannot provide zero order release, removal of remaining matrix is necessary 
for implanted system. 
1.5.3. Dissolution and diffusion - controlled release system: 
         Normally, therapeutic systems will never be dependent on dissolution only or 
diffusion only. In practice, the dominant mechanism for release will over shadow 
other processes enough to allow classification as either dissolution rate limited or 
diffusion controlled.  
Partially soluble membrane system 
The drug is encapsulated in a partially soluble polymer (a polymer that has 
domains that dissolve with time). The drug diffuses through the pores in the polymer 
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coat. For example, a cellulose acetate and HPMC mixture is coated on to the drug 
particles. 
                                                     GI fluids 
                                          
 
Figure 1.5: Partially soluble membrane system 
Matrix system: 
Matrix system encapsulate the drug in a membrane coating, where dissolution 
of the drug in the fluid that penetrates in to the core and diffusion of the drug from 
the core across the polymer membrane makes for a diffusion and dissolution 
controlled system.  
The drug is sparingly soluble in this case, so the release rate is slow and has 
significant influence on the diffusion of drug across the membrane. 
Advantages:  
 Easier to produce than reservoir devices.  
 Can deliver high – molecular weight compounds.  
 Removal from implant sites is not necessary. 
Disadvantages:  
 Difficult to control kinetics owning to multiple process of release.  
 Potential toxicity of degraded polymer.  
 
 
 
Drug       
Drug 
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1.5.4. Ion exchange systems: 
 These are salts of cationic or anionic exchange resins or insoluble complexes 
in which drug release results from exchange of bound drug ions that are normally 
present in GI fluids.   
The use of ion exchange resins to prolong the effect of drugs is based on the 
principle that positively or negatively charged therapeutic molecules combined with 
appropriate resins yield insoluble poly salt resonates. 
1.5.5. Osmotically controlled systems:   
This device is fabricated as tablet that contains water soluble osmotically 
active drug, of that was blended with osmotically active diluents by coating the tablet 
with a cellulose triacetate barrier which functions as a semi permeable membrane. A 
laser is used to form a precision orifice in the barrier, through which the drug is 
released due to development of osmotic pressure difference across the membrane, 
when it is kept in water.  
  Advantages: 
 Zero order release rates are obtainable. 
 Preformulation is not required for different drugs. 
 Release of drug is independent of the environment of the system. 
 Disadvantages: 
 System can be much more expensive than conventional counter parts. 
 Quality control is more extensive than most conventional tablets. 
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Figure 1.6:  Osmotically controlled systems 
1.5.6. pH independent formulations: 
       A buffered controlled release formulation is prepared by mixing a basic or acidic 
drug with or more buffering agents, granulating with appropriate pharmaceutical 
excipients and coating with GI fluid permeable film forming polymer. When GI fluid 
permeates through the membrane the buffering agent adjusts the fluid inside to 
suitable constant pH thereby rendering a constant rate of drug release. 
 
  
 
 
 
 
 
 
Figure 1.7:  Drug delivery from environmentally pH sensitive release systems 
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1.5.7. Altered density formulations: 
        Several approaches have been developed to prolong the residence time of drug 
delivery system in the gastrointestinal tract. 
          High-density approach 
          Low-density approach 
1.6. Matrix tablets:                 (Vyas S.P.and Khar R.K., 2002; Aulton M.E., 2007; 
F.A.A. Adam. et. al., 2007; http://www.pharmainfo.net) 
A matrix system consists of active and inactive ingredients, that are 
homogeneously dispersed and mixed in the dosage form. It is by far the most 
commonly used oral controlled release technology and the popularity of the matrix 
systems can be attributed to several factors which will be discussed in the later 
section. The release from matrix type formulations governed by Fick’s first law of 
diffusion.  
J = dQt/dt = - D dC/dx 
J is flux, or rate of diffusion, while Q is the amount diffused per unit of time t, and D 
is diffusion coefficient. 
1.6.1. Advantages of matrix system: 
Unlike reservoir and osmotic systems, products based on matrix design can be 
manufactured using conventional processes and equipments. Secondly, development 
cost and time associated with the matrix system generally are viewed as variables, and 
no additional capital investment is required. Lastly, a matrix system is capable of 
accommodating both low and high drug loading and active ingredients with a wide 
range of physical and chemical properties. 
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1.6.2. Limitations of the matrix systems:  
As with any technology, matrix systems come with certain limitations. First, 
matrix systems lack flexibility in adjusting to constantly changing dosage levels as 
required by clinical study outcome. When new dosage strength is deemed necessary, 
more often than not a new formulation and thus additional resources are expected. 
Furthermore, for some products that require unique release profiles (dual release or 
delayed plus extended release), more complex matrix-based technologies such as 
layered tablets are required. 
1.6.3. Types of matrix systems: 
The matrix system can be divided into two categories depending on the types 
of retarding agent or polymeric materials. 
 (a) Hydrophobic matrix system: 
This is the only system where the use of polymer is not essential to provide 
controlled drug release, although insoluble polymers have been used. As the term 
suggests, the primary rate-controlling components of hydrophobic matrix are water 
insoluble in nature. These ingredients include waxes, fatty acids, and polymeric 
materials such as ethyl cellulose, methyl cellulose and acrylate copolymer. To 
modulate drug release, it may be necessary to incorporate soluble ingredients such as 
lactose into formulation. The presence of insoluble ingredient in the formulations 
helps to maintain the physical dimension of hydrophobic matrix during drug release. 
As such, diffusion of active ingredient from the system is the release mechanism, and 
the corresponding release characteristic can be described by Higuchi equation known 
as square root of time release kinetic. The square root of time release profile is 
expected with a porous monolithic, where the release from such system is 
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proportional to the drug loading. In addition, hydrophobic matrix systems generally 
are not suitable for insoluble drug because the concentration gradient is too low to 
render adequate drug release. As such, depending on actual ingredient properties or 
formulation design, incomplete drug release within the gastrointestinal transit time is 
a potential risk and need to be delineated during the development. With the growing 
needs for optimization of therapy, matrix systems providing programmable rates of 
delivery become more important. Constant rate delivery always has been one of the 
primary targets of controlled release system especially for drug with narrow 
therapeutic index. 
 (b) Hydrophilic matrix system: 
The primary rate limiting ingredients of hydrophilic matrix are polymers that 
would swell on contact with aqueous solution and form a gel layer on the surface of 
the system. When the release medium (i.e. water) is thermodynamically compatible 
with a polymer, the solvent penetrates into the free spaces between macromolecular 
chains. The polymer may undergo a relaxation process, due to the stress of the 
penetrated solvent, so that the polymer chains become more flexible and the matrix 
swells. This allows the encapsulated drug to diffuse more rapidly out of the matrix. 
On the other hand, it would take more time for drug to diffuse out of the matrix since 
the diffusion path is lengthened by matrix swelling. Moreover, it has been widely 
known that swelling and diffusion are not the only factors that determine the rate of 
drug. For dissolvable polymer matrix, polymer dissolution is another important 
mechanism that can modulate the drug delivery rate. While either swelling or 
dissolution can be the predominant factor for a specific type of polymers, in most 
cases drug release kinetics is a result of a combination of these two mechanisms. The 
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presence of water decreases the glassy-rubbery temperature (for HPMC from 184°C 
to below 37°C), giving rise to transformation of glassy polymer to rubbery phase (gel 
layer). The enhanced motility of the polymeric chain favours the transport of 
dissolved drug. Polymer relaxation phenomena determine the swelling or volume 
increase of the matrix. Depending on the polymer characteristics, the polymer amount 
in the rubbery phase, at the surface of the matrix, could reach the disentanglement 
concentration; the gel layer varies in thickness and the matrix dissolves or erodes. The 
concentration at which polymeric chains can be considered disentangled was 
demonstrated to correspond to an abrupt change in the rheological properties of the 
gel. This showed a relationship between rheological behaviour of HPMC gels and 
their erosion rate, conforming that the polymer-polymer and polymer-water 
interaction are responsible for the gel network structure and its sensitivity to erosion. 
In turn, they affect drug release rate in the case of poorly soluble drugs. Swelling 
controlled release systems are based upon these principles. Due to the viscoelastic 
properties of the polymer which are enhanced by the presence of cross-linked 
network, anomalous penetrant transport can be observed. This behaviour is bound by 
pure Fickian diffusion and case II transport. Therefore, transport can be reduced to 
three driving forces. The penetrant concentration gradient, polymer concentration 
gradient and osmotic force behavior are observed as a result of polymer network. 
Appropriate polymer can counterbalance normal Fickian diffusion by hindering the 
release of embedded drug, leading to an extended period of drug delivery, and 
possibly zero-order release.  
Drug release from swellable matrix tablets can be affected by glassy-rubbery 
transition of polymer (as a result of water penetration into the matrix where 
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interaction among water, polymer and drug or fillers is considered as the primary 
factor for release control) and the various formulation variables, such as polymer 
grade and type, drug to polymer ratios, drug solubility, drug and polymer particle 
sizes, compaction pressure and presence of additives or excipients in the final 
formulation. They concluded that, the release rate and mechanism of atenolol releases 
from hydrophobic and hydrophilic matrices are mainly controlled by the drug to 
polymer ratio. The results also showed that an increase in the concentration of fillers 
resulted in an increase in the release rate of the drug from matrices and hydrophilicity 
or hydrophobicity of the fillers had no significant effect on the release profile. 
Regarding the mechanism of release, the results showed that in most cases the drug 
release was controlled by both diffusion and erosion depending on the polymer type 
and concentration. On the other hand, incorporation of water soluble fillers like 
polyethylene glycol, lactose and surfactant into gel forming matrices can improve 
phenomenon of insufficient drug release, because these excipients can enhance the 
penetration of the solvent or water into the inner part of matrices, resulting in drug 
release from the matrices. 
(c) Lipid matrix system: 
           These materials manufactured by the lipoid waxes and related ingredients. 
Active form of drug from the dosage form release the content such a matrices 
followed by either diffusion or erosion. A drug release properties are mainly depends 
on the absorption medium fluid component than hydrophobic polymers. Either Stearyl 
alcohol or stearic acid mixed with carnauba wax it has been mainly applicable for 
release retarding polymer in sustained release formulation of tablet.  
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(d) Biodegradable matrix system:           
 These types of polymer are biodegraded either by enzymatic or non 
enzymatic process. It contains the polymeric substance which is composed of 
monomeric linking to other functional group and gives unstable linkage in the 
backbone. Consist of the polymers which comprised of monomers linked to one 
another functional groups and have unstable linkage in the backbone. Finally the 
biodegraded material is excreted in the enzymatic process. Examples of naturally 
obtaining type polymers such as protein and polysaccharides; modified 
synthesized process of natural polymers; synthetic polymers like aliphatic poly 
ester and poly anhydride. 
1.6.4. Polymers used in hydrophilic matrices:     
  (F.A.A. Adam, et. al., 2007) 
Hydrogel polymers were much investigated in literature on basis of drug 
release and release mechanism from hydrophilic matrix tablets as well as pellets. 
HPMC polymers achieve considerable attention due to their unique properties, and 
they can display good compression characteristics, including when directly 
compressed. They are nontoxic and can accommodate high level of drug loading, and 
also having adequate swelling properties that allows rapid formation of an external gel 
layer which retards or plays a major role in controlling drug release. 
Furthermore, HPMC polymers are well known as pH-independent materials, this 
advantage enable them to withstand fluctuations of pH induce by intra and 
intersubject variations of both gastric pH and gastrointestinal transit time. They have 
been used alone or in combination in formulation of matrix tablets, therefore the 
hydrophilic gel forming matrix tablets are extensively used for oral extended release 
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dosage forms due to their simplicity, cost effectiveness and reduction of the risk of 
systemic toxicity which happens as a result of dose dumping.   The release 
of diclofenac sodium from a mixture of HPMC, Carbopol 940, and lactose as water 
soluble fillers. The results showed that the combination of hydrogels retarded the drug 
better than single polymer. The principal advantage of HPMC matrix formulations is 
the drug release rates are generally independent of processing variables such as 
compaction pressure, drug particle size, increasing of initial granulation liquid and 
incorporation of lubricants.  
The relationship between particle size, tensile strength and the viscosity grade 
of HPMC was complicated. At smaller particle size, an increase in the viscosity grade 
of HPMC resulted in a reduction in the tensile strength of its compacts. However, at 
the large particle size, the tensile strength of HPMC compacts decreased with an 
increase in viscosity grade. For HPMC K100M, there was an increase in tensile 
strength. The combination of HPMC and HPC at different ratios was investigated. 
Increasing the HPMC-HPC ratio increased both the particle size of granules and the 
tablet hardness. The drug release of HPMC matrix tablets was slightly influenced by 
type and concentration of diluents, but the viscosity grade of the polymer did not 
affect the release mechanism. 
An  increase in crushing strength of tablets made of Macrogol 6000 and 
HPMC, due to an increase in compression force during tableting stage and the 
dissolution of formulated tablet was significantly affected by increasing HPMC 
concentration. 
Once daily propranolol extended release tablets using HPMC polymer as a 
retarding agent. The mechanism of the drug release from HPMC matrix tablet 
Ibuprofen sustained Release Tablets                             Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 30 
followed non-Fickian diffusion, while the in vivo absorption and in vitro dissolution 
showed a linear relationship. 
Other polymers used in hydrophilic matrix preparations include poly ethylene oxide, 
hydroxypropyl cellulose and hydroxyl ethyl cellulose. 
Xanthan gum (XG) was widely used as a thickening agent in food industries, 
but recently introduced in pharmaceutical formulations It is a high molecular weight 
extracellular heteropolysaccharide, produced by fermentation with the gram-negative 
bacterium Xanthamonas campestris. XG shows excellent swelling properties and the 
swelling of the XG polymer matrix shows a square root of time dependence whereas 
drug release is almost time independent.  
Carbopol is a derivative of polyacrylic acid. It is a synthetic, high molecular 
weight, crosslinked polymer. It is readily hydrates, absorbs water and swell. In 
addition, its hydrophilic nature and highly crossliked make it a potential candidate and 
has been used in controlled release drug delivery systems. In the case of tablets 
formulated with Carbopol polymer, the drug is entrapped in the glassy rubbery core in 
the dry state. It forms a gelatinous layer upon hydration. However, this gelatinous 
layer is significantly different structurally from the traditional matrix tablets. The 
hydrogel is not entangled chains of polymer, but discrete microgel made up of many 
polymer particles in which the drug is dispersed. The crosslinked network enables the 
entrapment of drug in the hydrogel domains. Since these hydrogels are not water 
soluble they do not dissolve, and erosion in the manner of linear polymer does not 
occur. Rather, when the hydrogel is fully hydrated, osmotic pressure from within 
works to break up the structure, essentially by sloughing off discrete pieces of the 
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hydrogel. This hydrogel remains intact, and the drug continues to diffuse through the 
gel layer at a uniform rate. 
It is well recognized that key formulation variables are matrix dimension and 
shape, polymer level and molecular weight, as well as drug loading and solubility. 
Other factors such as tablet hardness, type of inactive ingredients and processing 
normally play secondary roles. The choice of manufacturing process such as direct 
blending or granulation typically does not affect product performance significantly, 
although exception does exist. In general, processing and scale-up associating with 
hydrophilic matrices are more robust than other controlled release systems. 
1.6.5. Drug release from matrix systems:   
 (http://www.pharmainfo.net) 
Drug in the outside layer exposed to the bathing solution is dissolved first and 
then diffuses out of the matrix. This process continues with the interface between the 
bathing solution and the solid drug moving toward the interior. It follows that for this 
system to be diffusion controlled, the rate of dissolution of drug particles within the 
matrix must be much faster than the diffusion rate of dissolved drug leaving the 
matrix. Derivation of the mathematical model to describe this system involves the 
following assumptions: 
a) A pseudo-steady state is maintained during drug release,  
b) The diameter of the drug particles is less than the average distance of drug 
diffusion through the matrix, 
c) The bathing solution provides sink conditions at all times. 
The release behavior for the system can be mathematically described by the following 
equation, 
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dM /dh = Co.dh – Cs/2……………1 
Where, 
dM = Change in the amount of drug released per unit area 
dh = Change in the thickness of the zone of matrix that has been depleted of drug 
Co = Total amount of drug in a unit volume of matrix 
Cs = Saturated concentration of the drug within the matrix.  
Additionally, according to diffusion theory,  
dM = (Dm.Cs)/h . dt...............2 
dM = Change in the amount of drug released per unit area 
dh = Change in the thickness of the zone of matrix that has been depleted of drug 
Co = Total amount of drug in a unit volume of matrix 
Cs = Saturated concentration of the drug within the matrix. 
By combining equation 1 and 2 and integrating 
M = [Cs . Dm . (2 Co - Cs . t )]1/2 ……. 3 
When the amount of drug is in excess of the saturation concentration, then 
M = [Cs . Dm . Co . t]1/2 . ……………4 
Equation 3 and 4 indicates the amount of drug release to the square-root of time. 
Therefore, if a system is predominantly diffusion controlled, then it is expected that a 
plot of the drug release vs. square root of time will result in a straight line. Drug 
release from a porous monolithic matrix involves the simultaneous penetration of 
surrounding liquid, dissolution of drug and leaching out of the drug through tortuous 
interstitial channels and pores. The volume and length of the openings must be 
accounted for in the drug release from a porous or granular matrix, 
M = [2 D. Ca . p / T. (2 CO – p. Ca ) t]1/2 ….. 5 
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Where, p = Porosity of the matrix 
t = Tortuosity 
Ca = solubility of the drug in the release medium 
Ds = Diffusion coefficient in the release medium 
T = Diffusional pathlength 
For pseudo steady state, the equation can be written as, 
M = [2 D . Ca . CO ( p / T ) t]1/2……….6 
The total porosity of the matrix can be calculated with the following equation, 
p = pa + Ca / ρ + Cex / ρex ..…….…. 7 
Where, 
p = Porosity 
ρ = Drug density 
pa = Porosity due to air pockets in the matrix 
ρex = Density of the water soluble excipients 
Cex = Concentration of water soluble excipients 
For the purpose of data treatment, Equation 7 can be reduced to, 
M = k . t1/2 ..………….. 8 
Where k is a constant, so that the amount of drug released versus the square root of 
time will be linear. If the release of drug from matrix is diffusion-controlled. In this 
case, the release of drug from a homogeneous matrix system can be controlled by 
varying the following parameters, 
• Initial concentration of drug in the matrix 
• Porosity 
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• Tortuosity 
• Polymer system forming the matrix 
• Solubility of the drug. 
1.7. Methods used in tablet manufacturing:   (Lieberman H.A. and Lachman L., 
1999; Ansel H.C., 2009) 
                A. Wet granulation 
                B. Dry granulation      
                C. Direct compression 
Granulation: 
                Generally the powders material cannot be punching directly into tablet form, 
because (a) the material should not have bonding a property to each other into 
compaction and (b) insufficient flow character from the hopper into die cavity. For 
this reason and this nature of material we can go for granulation methods. 
The reason for granulation: 
  Become the pharmaceutical ingredient are free flowing 
  Increase the denseness of  ingredient 
  We can formulate uniform granular size that does not existing apart  
  Produce better  compression  characteristic  of  drug 
  Controlling  the  rate of  drug release from the dosage form 
  Reduce  dust in granulation technique 
  The  appearance  of  tablet can be achieved 
A. Wet granulation: 
           Size reduction of active ingredient and inactive ingredient, proper mixing of 
crushed powders, preparation of binder solution by using standard binder, pouring the 
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binding agent with powder mixture to form coherent mass, the wet mass is screening 
using 6 to 12 sieve mesh, drying the shifted granules, sieving prepared granules with 
lubricant and glidant, mixing screened granules with lubricant and glidant, finally 
compressed into tablet form.  
Advantages: 
 Powder material is converted into granular form by adding binding solution, 
the use of binder it’s coating the each powder material to get a granules which having 
better cohesiveness and compressibility for manufacturing of tablet.  
 If an active component it has been high label claim and also improper flow 
characteristic can be prepared by wet granulation technique to acquire excellent flow 
of granules and its granular material having cohesiveness for punching.  
 Uniform distribution of active ingredient as well as uniform active content 
quantity of prepared dosage form. 
 In many pharmaceutical ingredient can cause the dust and airborne pollute it 
could be handling without producing this problem by granulation method. 
 In these methods prevent the agglomeration of ingredient in a homogeneous 
powder mixture under processing, shifting and handling.  
 Controlled release dosage form can be developed by the manufacturing 
scientist using better binding agent and polymer or solvent. 
 This procedure entrapment of air in the material can be reduced.  
Disadvantages: 
 It needs a number of equipments in the production area. 
 There is a chances of pollute than the direct compression method. 
Ibuprofen sustained Release Tablets                             Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 36 
 In these method timing period is increase because moistening the material and 
drying process. 
 This method not suitable for sticky ingredient and hygroscopic substance. 
B. Dry granulation: 
            In dry granulation size reduction of active ingredient and inactive ingredient, 
mixing of milled material, directly compressed into tablet, further the prepared tablet 
is milled this process called slugging, sieving of slug material, finally mixing with 
lubricant and glidant and tablet punching. 
Advantages: 
 In this method the material are highly heats sensitive and destroyed in 
moisture condition so we can formulate by dry granulation method. 
 It needs less space for placing the equipment and processing step than other 
methods. 
 The ingredient cost is smaller in extent. 
Disadvantages: 
 For this method, either the active material or inactive material should have 
binding properties and cohesive nature. 
 The ingredient must be in the nature of either crystalline or amorphous form. 
C. Direct compression: 
           Size reduction of active component and inactive component, mixing of milled 
ingredients, tablet compression. 
Advantages: 
 The exposing of active component to moisture and thermal can be prevented. 
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 These methods the cost of preparation can be minimized and reduce the labor 
cost. 
 Tablet manufactured by this process very easy to disintegrating molecule from 
the dosage form.  
 The equipment like granulators and dryers and solvent are not needed in 
manufacturing of tablets by this method. 
Disadvantages: 
 The uniformity of color is difficult to achieve in manufacturing of tablets. 
 In this process cost of materials is a great vertical extent. 
 In this method produce dust and air pollute during manufacturing process.  
 Content uniformity is not maintained, because agglomeration and separation 
of drug molecule it will occur in transferring from hopper into die cavity.      
1.8. ARTHRITIS:  
(Tripathi K.D., 2003; Rang A.P., et al., 2001; Brunton L., et al., 2008) 
“Arthritis” literally means “inflamed joints”. Arthritis primarily affects the 
joints; it also attacks muscles and connective tissues of the surrounding organs. 
Arthritic disease stems from injuries, defects in the immune system, wear and tear on 
the joints, infections or genetic predisposition. 
A. Osteoarthritis: 
A degenerative joint disease and the most common form of arthritis and joint 
disorders, is the gradual deterioration of cartilage, usually in the larger, weight 
bearing joints such as the hips, knees, and spine. This wear and tear is normal 
process predominantly found in people of age 55 and older. Among those younger 
than 45, it occurs more often in men.  The joints are not always inflamed; the 
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articular cartilage may begin to flake and crack, due to over use or injury. In severe 
cases the underlying bone becomes thickened and distorted. Scar tissue may then 
replace damaged cartilage. If movement becomes painful and restricted, lessened use 
of the associated muscles will lead to their atrophy. 
B. Rheumatoid arthritis: 
Rheumatoid arthritis is traditionally considered a chronic, inflammatory 
autoimmune disorder that causes the immune system to attack the joints. It is a 
disabling and painful inflammatory condition, which can lead to substantial loss of 
mobility due to pain and joint destruction. Rheumatoid arthritis is a systemic disease, 
often affecting extra articular tissues throughout the body including the skin, blood 
vessels, heart, lungs and muscles.        
The joint lining, called the synovium, becomes inflamed in cases of 
rheumatoid arthritis, leading to pain, stiffness, warmth, redness and swelling. These 
inflamed cells release an enzyme that may even digest cartilage and bone. 
1.8.1   Biochemical mechanism: 
The normal synovial lining of diarthodial joints is a delicate tissue layer up to 
three cells thick and a loosely arranged stroma with connective tissue, 
microvasculature and lymphatics. Inflammatory synovitis is the key pathological 
feature in rheumatoid arthritis. Its characteristics are synovial hyperplasia, 
inflammatory cell infiltration and vascularity. Initially edema and fibrin deposition 
predominate. Subsequently, there is synovial lining layer hyperplasia involving 
macrophage and fibroblast like synoviocytes. This hyperplasia is accompanied by 
infiltration of T cells, B cells, macrophages and plasma cells in the sublining layer. 
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A number of different pathological mechanisms are involved in rheumatoid 
arthritis. Lymphocytes have an important role and many inflammatory cells in the 
synovial sublining layer are lymphocytes, especially T cells.  
 
 
 
 
                        
 
 
Figure 1.8: The Pathophysiology of Rheumatoid Arthritis 
 
1.8.2. Symptoms:  
The exacerbation of the disease peaks at only certain times of the day and the 
cardinal symptoms of rheumatoid arthritis include: 
• Stiffness, swelling and pain of one or more joints of the body characteristically 
severe in the morning, fatigue and weakness.  
• Stiffness following periods of immobility, which gradually improves with 
movement.  
• Rheumatoid nodules (lumps of inflamed cells) under the skin usually found on 
the bony part of the fore arm, ankle and fingers.  
• Minor fever, anemia and weight loss. 
 
 
Ibuprofen sustained Release Tablets                             Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 40 
1.8.3. Treatment: 
Pharmacological treatment of rheumatoid arthritis can be divided into 
• Disease modifying anti-rheumatic drugs  
• Anti-inflammatory agents and analgesics. 
• DMARDs have been found to produce durable remissions and delay or 
halt disease progression. In particular they prevent bone and joint damage 
from occurring secondary to the uncontrolled inflammation.  
1.8.4. Disease modifying anti-rheumatic drugs (DMARDs): 
DMARDs can be further subdivided into Xenobiotic agents and biological 
agents. Xenobiotic agents are those DMARDs that do not occur naturally in the 
body, as opposed to biologicals. 
Xenobiotics include, 
 Azathioprine, Cyclosporine, D-penicillamine, gold salts, Leflunomide, Minocycline, 
Hydroxychloroquine, Methotrexate, and Sulfasalazine.  
Biological agents: 
Tumor necrosis factor (tnf α) blockers - Etanercept (Enbrel), Infliximab (Remicade),        
Interleukin-1 blockers     - Anakinra  
Anti-B cell (CD20) antibody    - Rituximab   
1.8.5. Anti-inflammatory agents and analgesics:  
The treatment of arthritic conditions relies on medicines that fight joint 
swelling, stiffness and pain. Circadian rhythm affects the arthritic medication. 
NSAIDs reduce the swelling, stiffness and pain of arthritis. Taking the medicines at 
the wrong time of day compromises their effectiveness and increases the risk of side 
effects such as indigestion, stomach ulcers, headache, anxiety and dizziness. 
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Chronotherapy provides ways of increasing the effectiveness and safety of arthritic 
medications.  
Anti-inflammatory agents include, 
A. Glucocorticoids:  
Non steroidal anti-inflammatory drugs also act as analgesics. 
B. Non steroidal anti -inflammatory drugs:  
NSAIDs are drugs with analgesic, antipyretic and anti inflammatory effects 
that reduce pain, fever and inflammation. The term "non steroidal" is used to 
distinguish these drugs from steroids, which (among a broad range of other effects) 
have a similar eiconoside depressing, anti inflammatory action.  
Mechanism of action:  
Most NSAIDs act as non selective inhibitors of the enzyme cyclooxygenase, 
inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) 
isoenzymes.  
Cyclooxygenase catalyzes the formation of prostaglandins and thromboxane 
from arachidonic acid (Derived from the cellular phospholipid bilayer by 
phospholipase A2).  
 
 
 
 
 
 
Figure 1.9: Mechanism of action of NSAIDs 
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1.8.6. Classification of NSAIDs: 
    A. Chemical classification: 
Table 1.1: Classification of NSAIDs 
 
 
 
 
 
 
B. Classification based on COX selectivity:  
1. Non COX selective NSAIDS: 
Aspirin, Indomethacin, Diclofenac, Piroxicam, Ibuprofen, Naproxen,    
Mefenamic acid. 
2. Preferential COX-2 inhibitors: 
Nimesulide, Meloxicam, Nabumetone, Ibuprofen 
3. Highly selective COX-2 inhibitors:  
1st generation :  Celecoxib, Rofecoxib 
2nd generation :  Valdecoxib, Parecoxib, Etoricoxib, Lumiracoxib.
S.No. Category Drug 
1. Salicylates Aspirin 
2. Indoles Indomethacin 
3. Pyrazoles Phenyl butazone 
4. Fenamate Mefenamic acid 
5. Propionic acid Ibuprofen, Ketoprofen 
6. Phenyl acetic acid  Diclofenac, Ibuprofen, Flurbiprofen 
7. Oxicam Piroxicam, Tenoxicam, Meloxicam 
8. Sulphonanilide Nimesulide 
9. Coxibs Celecoxib, Rofecoxib,Valdecoxib, Parecoxib 
10 Alkanone Nabumetone 
11 Aryl propionic acid Naproxen 
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2. NEED AND OBJECTIVE 
  
Ibuprofen is a non-steroidal anti-inflammatory, analgesic and antipyretic 
agent. It is a prodrug of Diclofenac, in the inflammatory cells it gets converted into 
diclofenac and 4-hydroxy diclofenac. Ibuprofen has the more COX-2 specificity than 
diclofenac, as it is active only in inflammatory cells it has less GI stress than 
diclofenac. It has short biological half-life (4 hours), and the usual oral dosage 
regimen is 100 mg taken 2 times a day. 
The basic goal of therapy is to achieve a steady state blood or tissue level that 
is therapeutically effective and non-toxic for an extended period of time. Sustained 
release drug delivery systems, with an aim of improved patient compliance, better 
therapeutic efficacy, less side effects and reduced dosage regimen with less toxicity 
for treatment for many acute and chronic diseases. 
Non–Steroidal Anti-Inflammatory Drugs (NSAIDs) are considered to be the 
first line drug in the symptomatic treatment of rheumatoid arthritis, osteoarthritis and 
ankylosing spondylitis. Ibuprofen is one of the emerging NSAIDs molecules for 
arthritis treatment 
 To minimize the frequent dosing  
 To prolong the pharmacological effect and  
 To improve patient compliance, a sustained release formulation of Ibuprofen 
is very much desirable.  
Among the many techniques used for modulating the drug release profile, the 
most commonly used method is embedment of the drug into a polymer matrix.  
Ibuprofen Sustained Release  Tablets NEED AND OBJECTIVE 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 44 
The matrix may be formed by either dissolving or dispersing the drug uniformly 
in the polymer mass. Such polymer matrices can give,  
 Desirable release profiles 
 Cost effective manufacturing method and also  
 Broad regulatory acceptance.  
Hence, in the present work, an attempt is made to develop sustained-release 
matrix tablets of Ibuprofen, with the use of various hydrophilic polymers for their 
sustaining effect. Wet granulation technique is used for tablet formulation along with 
the addition of suitable additives by using of hydrophilic polymers of HPMC K15M, 
Carboxy methyl cellulose and Xanthan gum. 
Objectives of the work: 
To design of sustained release dosage form of Ibuprofen that will help in releasing 
only small quantities of drug over a prolonged period of time.  
 To study the effect of type of polymers and polymer concentration on release 
profiles of sustained release Ibuprofen formulations. 
 To study the different types of schemes on release profiles of sustained release 
Ibuprofen formulations. 
 To arrive at better formulation based on comparison amongst the studied ones. 
 To perform stability studies as per ICH guidelines. 
 
  
     
 
 
 
 
 
 
 
 
 
 
 
      Plan of Work 
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3. PLAN OF WORK 
 
 Literature survey 
 Selection and procurement of suitable drug candidate and excipients 
 Preformulation studies 
 Characterization of drug 
• Melting point determination 
• Solubility determination 
• UV spectra (λ max) 
• IR spectra 
• Loss on drying 
• Standard carve of  Ibuprofen 
• Percentage purity of drug 
 Drug polymer interaction study 
• Fourier transform Infra-Red (FTIR) spectroscopy 
• Differential Scanning Calorimetry (DSC) 
 Characterization of Powdered blend 
• Bulk density 
• Tapped density 
• Carr’s index 
• Hausner’s ratio 
• Angle of repose 
Ibuprofen Sustained Release Tablets                    PLAN OF WORK 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 46 
 Formulation of  Sustained release matrix tablet of   Ibuprofen 
 Evaluation of  Sustained release matrix tablet  of Ibuprofen  
• Appearance 
•  Dimensions ( Thickness and Diameter) 
• Hardness 
• Percent friability 
• Weight variation test 
• Drug content of Ibuprofen  (assay) 
• In-vitro dissolution studies 
• Kinetic of In-vitro Drug Release 
 Stability studies 
 Result and discussion 
 Summary and conclusion   
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4. LITERATURE REVIEW 
 
Sahoo S.K., et al., (2008): In the present study Ibuprofen gelatin micropellets 
were prepared by cross linking technique using glutaraldehyde has a cross linking 
agent. The effect of the drug polymer ratio, temperature of oil phase amount of 
glutarldehyde and stirring micropellets having an entrapment efficacy, micropellets 
size and drug release characteristics spherical micropellets having an entrapment 
efficiency of 57-97% were obtained. 
Keny R.V., et al., (2009): The present study was aimed to develop once daily 
extended release matrix tablets of minocycline hydrochloride, using hydroxyl propyl 
methyl cellulose either alone or in combination with ethyl cellulose as the matrix 
material in different proportions. The formulated tablets were also compared with a 
marketed product. The results of the dissolution study indicate that formulations FC-
IV, FC-V, FC-VI, shows maximum drug release upto 24 hr. Drug release from matrix 
occurred by combination of two mechanisms diffusion of tablet matrix and erosion of 
tablet surface which was reflected from Higuchi’s model and Erosion plot. 
Nasra M.A., et al., (2007): The potential of matrix, multilayer and 
compression coated tablets of metronidazole to reach the colon intact has been 
investigated in vitro, using pectin as a carrier. Matrix tablets containing various 
proportions of pectin were prepared by wet granulation and direct compression 
techniques. In vitro release studies indicated that matrix and multilayer tablets failed 
to control the drug release in the physiological environment of stomach and small 
intestine, compression coated tablet formulations F13, F14 and F12 released about 
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70.25% ± 9.9%, 51.3% ± 5.45% and 20% ± 5.01% drug respectively at the end of 24 
hours. These tablets exhibited no change either in physical appearance or dissolution 
pattern after storage at ambient temperature (25°C) for 12 months. 
Manjanna K.M., et al., (2009): The objective of the present study was 
microencapsulate the Ibuprofen (NSAIDs) by ionotropic gelation technique by using 
sodium alginate as hydrophilic carrier in various polymer interactions were observed 
in FT-IR studies. In-vitro drug release profile of Ibuprofen from microbeads was 
examined in simulated gastric fluid pH1.2 for initial 2 h, mixed phosphate buffer 
pH6.8 upto 6 h and simulated intestinal pH 7.2 at end of 24 h studies. The release of 
drug from the microbeads was pH dependent, showed negligible drug release in 
pH1.2. Under neutral conditions the beads will swell and the drug release depend on 
the swelling and erosion process resulting optimum level of drug released in a 
sustained manner and exhibited zero-order kinetics followed by super case-II 
transport. 
Ganesan V., et al., (2008): The objective of the study was to develop guar 
gum matrix tablets for oral controlled release of Ambroxol hydrochloride. According 
to the theoretical release profile calculation, a twice daily sustained release 
formulation should release 19.6 mg of Ambroxol hydrochloride in 1 hour like 
conventional tablets, and 5.2 mg per hour upto 12 hours. Ambroxol hydrochloride 
matrix tablets containing either 30%wt/wt of low viscosity (F-III), 25% wt/wt 
medium viscosity (F-VI) or 20% wt/wt high viscosity (F-IX) guar gum showed 
sustained release. Applying exponential equation, the selected formulations F-III and 
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F-VI showed diffusion-dominated drug release and followed first order kinetics. The 
mechanism of drug release from F-IX was diffusion coupled with erosion. 
Gothi G.D., et al., (2010): In the present investigation an attempt was made to 
reduce the frequency of dose administration, to prevent nocturnal heart attack and to 
improve the patient compliance by developing extended release (ER) matrix tablet of 
metoprolol succinate. The effect of concentration of hydrophilic (HPMC K100M, 
Xanthan gum) on the release rate of metoprolol succinate was studied. 
Anton S.A., et al., (2009): The objective of the present work was to develop 
sustained release matrix tablets of Ondansetron Hydrochloride (5mg) formulated 
employing Hydroxy propyl Methyl Cellulose (HPMC), polymer and the sustained 
release behavior of the tablets was investigated. Tablets were prepared by wet 
granulation methods. 
Krishnaiah Y.S.R., et al., (2004): The objective of the present study is to 
carry out pharmacokinetic evaluation of oral controlled release formulation (guar 
gum-based three layer matrix tablets) containing highly soluble metoprolol tartrate as 
a model drug. The plasma concentration of metoprolol tartrate was estimated by 
reverse-phase HPLC. The pharmacokinetic parameters were calculated from the 
plasma concentration of metoprolol tartrate versus time data. The results of the study 
indicated that guar gum three-layer matrix tablets were able to provide oral controlled 
delivery of highly water-soluble drug such as metoprolol tartrate in humans. 
Mishra B., et al., (2005): The present study aimed to formulate and evaluate 
hydrophilic matrix tablets of diltiazem hydrochloride to achieve a controlled and 
sustained drug release with reduced frequency of drug administration, reduced side 
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effects and improved patient compliance. Matrix tablets of diltiazem hydrochloride 
were prepared using polymers like hyroxypropyl methylcellulose (HPMC K15M, 
HPMC K4M), sodium carboxy methylcellulose (SCMC) and Guar gum, and different 
diluents like lactose, starch, microcrystalline cellulose. 
Chandria M., et al., (2009): The present investigation attempt has been made 
increase therapeutic efficacy, reduce frequency of administration and improve patient 
Compliance, by developing sustained release matrix tablets of Zidovudine, were 
developed by using drug polymer ratio of kollidon SR, HPMC K15M and HPMC 
K100M as matrix tablet formulation were compressed by direct compression and wet 
granulation method. Compressed tablets were evaluated for uniformity of weight, 
content of active ingredient, friability, hardness, thinkess, in-vitro dissolution, and 
swelling index, all formulation showed compliance with pharmacopoeial standards. 
Morkhade D.M., et al., (2007): Natural gum, damer was investigated as a 
novel microencapsulating material for sustained drug delivery. Microparticles were 
prepared by oil-in-oil emulsion solvent evaporation method. Ibuprofen and diltiazem 
hydrochloride were used as model drugs. in-vitro drug release kinetics.. The increase 
in gum:drug ratio showed an increase in particle size, encapsulation efficiency and 
decrease in drug release rate in all cases. Drug release profiles of all microparticles 
followed zero order kinetics.  
Saptarshi D., et al., (2010): An attempted was to formulate the oral sustained 
release metformin hydrochloride matrix tablets by using hydroxyl methyl cellulose 
polymer (HPMC) as rate controlling factor and to evaluate drug release parameters as 
per various release kinetic models. It is observed that the basic goal of therapy in the 
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development of metformin hydrochloride release dosage form is to increase 
bioavailability; reduce risk of hospitalization, deliver drug at a near constant rate for 
approximately 12h; independent of food intact and gastrointestinal pH. The dry 
granulation technique was used to compress the tablet as powder showed the poor 
flowability; wet granulation technique was not selected for the present work. 
Sarojini S., et al., (2010): The purpose investigation highlights the 
formulation and optimization of floating tablets of Theophylline as a model drug. 
Formulations were optimized for type of filler and different concentration of 
Polyethylene oxide. 
Tabandeh H., et al., (2003): A sustained release tablet formulation should 
ideally have a proper release profile insensitive to moderate changes in tablet hardness 
that is usually encountered in manufacturing. In the study, matrix Aspirin 
(acetylsalicylic acid) tablets with ethyl cellulose (EC), Eudragit RL100, Eudragit 
S100 were prepared by direct compression. The release behaviors were then studied 
in two counterpart series of tablets with hardness difference of three Kp units, and 
compared by non-linear regression analysis. 
Varshosaz J.,  et al., (2002): The buccoadhesive controlled-release tablets for 
delivery of Nifedipine were prepared by direct compression of carboxymethyl 
cellulose (CMC) with carbomer (CP), which showed superior bioadhesion properties 
compared to polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl 
methylcellulose (HPMC), and acacia in a modified tensiometry method in vitro. The 
tablets containing 30 mg of Nifedipine and various amounts of CMC and CP showed 
a zero-order drug release kinetic. 
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Yeole P.G., et al., (2006): In the present investigation, an attempt has been 
made to increase therapeutic efficacy, reduce frequency of administration, and 
improve patient compliance, by developing sustained release matrix tablets of 
Diclofenac sodium. Sustained release matrix tablets of Diclofenac sodium, were 
developed by using different drug:polymer ratios, such as F1(1:0:12), F2(1:0:16), 
F3(1:0:20), F4(1:0:24) and F5(1:0:28). Xanthan gum was used as matrix former, and 
microcrystalline cellulose as diluents. All the lubricated formulations were 
compressed using 8mm flat faced punches.  
Ghosh S., et al., (2009): The objective of the study was to develop matrix 
tablets for oral controlled release of Ibuprofen. Matrix tablets of Ibuprofen, using 
various viscosity of hydrophilic polymer HPMC in two different proportions, 
hydrophobic polymer ethyl cellulose and Guar gum were prepared by wet granulation 
method and subjected to in vitro drug release studies. The drug release from all 
HPMC matrix tablets followed various release kinetics, formulation no - F7 followed 
Higuchi kinetics. Furthermore, the results of the in vitro studies in pH 7.5 phosphate 
buffer medium showed that F7 tablets provided controlled release comparable with 
market sustained release formulation (Aeroff-SR tablets). 
Radika P.R., et al., (2008): Delayed release microspheres of Ibuprofen were 
formulated using enteric polymer, Cellulose acetate phthalate (CAP) prepared by 
solvent evaporation technique. The effect of various other modern enteric polymers 
such as HPMC, Eudragit L-100, Eudragit S-100 on the release of Ibuprofen from the 
CAP have been evaluated. 
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Soni T., et al., (2008): The development of a meaningful dissolution 
procedure for drug products with limited water solubility has been a challenge to the 
pharmaceutical industry. Ibuprofen (BCS Class II drug) is a non steroidal anti-
inflammatory drug. There is no official dissolution medium available in the literature. 
In the present study, parameters such as solubility, medium pH, surfactant type, 
dissolution behavior of formulations, and influence of sink conditions, stability, and 
discriminatory effect of dissolution testing were studied for the selection of a proper 
dissolution medium. 
Srinivas Mutalik., et al., (2008): The purpose of this study was to develop a 
once daily sustained release tablet of Ibuprofen using chitosan and an enteric coating 
polymer. Overall sustained release for 24 h was achieved by preparing a double-layer 
tablet in which the immediate release layer was formulated for a prompt release of the 
drug and the sustained release layer was designed to achieve a prolonged release of 
drug. Good equivalence in the drug release profile was observed when drug release 
pattern of the tablet containing chitosan and hydroxypropyl methylcellulose phthalate 
(M-7) was compared with that of marketed tablet.  
Umesh.D. Shivhare., et al., (2009): The objective of the present study was to 
develop “once daily” sustained release tablets of Ibuprofen by wet granulation using 
carboxy -polymethylene polymer. The drug excipient mixtures were subjected to 
preformulation studies while the tablets were subjected to physicochemical studies, in 
vitro drug release, stability studies and validation studies. 
Basak S.C., et al., (2010): Monolithic matrix tablets of Ambroxol 
Hydrochloride were formulated as sustained release tablets employing Hydroxy 
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Propyl Methyl Cellulose polymer, and the sustained release matrix tablets containing 
75mg Ambroxol hydrochloride were developed using different drug polymer ratios of 
Hydroxy Propyl Methyl Cellulose. Tablets were prepared by direct compression.  
Formulation was optimized on the basis of acceptable tablet properties and in vitro 
drug release. 
Yadav I.K. et al., (2010): The objective of the present study was to develop 
the oral sustained release matrix tablets of Ibuprofen using hydrophilic and 
hydrophobic polymers. Ibuprofen is a non steroidal anti-inflammatory agent used in 
symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing 
spondylitis and its biological half life is 4 hrs. Controlled release formulations of 
Ibuprofen (200 mg) were prepared by direct compression method. The drug release 
from optimized formulations F1, F4 and F7 was extended for a period of 12 h. The 
kinetic treatment to optimized formulations showed that the release of drug follows 
zero order model and Super Case II transport for F1 and F7. 
Suvakanta D., et al., (2010): In this paper were reviewed mathematical 
models used to determine the kinetic of drug release from drug delivery system the 
quantitative analysis of the values are obtained in dissolution/ release rate is easier 
when mathematical formula used to describe the process. The mathematical modeling 
can optimize to design therapeutic design of therapeutic device to yield information 
on the various efficacy of various release models. 
Kabir A.K., et al., (2009): Objective of this study was to develop a sustained 
release matrix tablet of Ibuprofen using hydroxypropyl methylcellulose (HPMC 
K15M and HPMC K100M CR) in various proportions as release controlling factor by 
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direct compression method. The results of dissolution studies indicated that the 
formulations F-2 and F-3 could extend the drug release up to 24 hours. From this 
study, a decrease in release kinetics of the drug was observed when the polymer 
concentration was increased. Kinetic modeling of in vitro dissolution profiles revealed 
the drug release mechanism ranges from diffusion controlled or Fickian transport to 
anomalous type or non-Fickian transport, which was only dependent on the type and 
amount of polymer used. The drug release followed both diffusion and erosion 
mechanism in all cases. 
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                                  5. DRUG AND EXCIPIENT PROFILE 
5.1. DRUG PROFILE :                               (IP, 2007; BP., 2009; Kabir, et al., 2009) 
5.1.1. IBUPROFEN: 
Chemically, Ibuprofen is described as 2-(4-isobutylphenyl)propionic acid and is a non-
steroidal compound, which exhibits high levels of anti-inflammatory, analgesic and 
antipyretic activities necessary for the effective treatment of rheumatoid arthritis and osteo-
arthritis. 
• Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), which relieves pain and 
swelling (inflammation). It is used to treat headaches, muscle aches, backaches, 
dental pain, menstrual cramps, arthritis, or athletic injuries. This medication is also 
used to reduce fever and to relieve minor aches and pains due to the common cold or 
flu.  
• This drug works by blocking the enzyme in your body that makes prostaglandins. 
Decreasing prostaglandins helps to reduce pain, swelling, and fever. 
• Ibuprofen is a racemic mixture of [+] S- and [-] R-enantiomers. 
Ibuprofen now-outdated nomenclature  iso-butyl-propanoic-phenolic acid) is a non-steroidal 
anti-inflammatory drug (NSAID) originally marketed as Brufen, and since then under various 
other trademarks the most notable ones being Nurofen, Advil, and Nuprin.  
It is used for relief of symptoms of arthritis, primary dysmenorrhea, fever, and as an 
analgesic, especially where there is an inflammatory component. 
 Ibuprofen is known to have an antiplatelet effect, though it is relatively mild and short-lived 
when compared with aspirin or other better-known antiplatelet drugs. In general, ibuprofen 
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also acts as a vasodilator, having been shown to dilate coronary arteries and some other blood 
vessels. 
Structure 
 
          (IUPAC) name   (RS)-2-(4-(2-methylpropyl) phenyl) propionic 
acid 
 
Table52.1: Physico – Chemical Properties of  Ibuprofen 
Description white or almost white colored crystalline powder 
Chemical name  2-(4-isobutylphenyl) propionic Acid 
Molecular formula C13H18O2  
Molecular weight 206.29 g/mol 
Melting point 75 - 770C 
Functional category Ibuprofen is used for the treatment of mild to moderate pain, 
inflammation and fever caused by many and diverse diseases 
Pharmacopoeial status Ph.Eur 
Storage conditions Ibuprofen should be stored at room temperature, between 15-
30°C (59-86°F). 
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Solubility Ibuprofen is very slightly soluble in water (<1 mg/mL) and 
readily soluble in organic solvents such as ethanol and 
acetone. 
 
Site and Mode of Action:  
Nonsteroidal anti-inflammatory drugs such as ibuprofen work by inhibiting the enzyme 
cyclooxygenase (COX), which converts arachidonic acid to prostaglandin H2 (PGH2). PGH2, 
in turn, is converted by other enzymes to several other prostaglandins (which are mediators of 
pain, inflammation, and fever) and to thromboxane A2 (which stimulates platelet aggregation, 
leading to the formation of blood clots). 
Like Aspirin, Indomethacin, and most other NSAIDs, ibuprofen is considered a nonselective 
COX inhibitor; that is, it inhibits two isoforms of cyclooxygenase COX-1 and COX-2.  
The analgesic, antipyretic, and anti-inflammatory activity of NSAIDs appears to be 
achieved mainly through inhibition of COX-2, whereas inhibition of COX-1 would be 
responsible for unwanted effects on platelet aggregation and the gastrointestinal tract.  
However, the role of the individual COX isoforms in the analgesic, anti-
inflammatory, and gastric damage effects of NSAIDs is uncertain and different 
compounds cause different degrees of analgesia and gastric damage. In order to 
achieve the beneficial effects of ibuprofen and other NSAIDS without gastrointestinal 
ulceration and bleeding, selective COX-2 inhibitors were developed to inhibit the 
COX-2 isoform without inhibition of COX-1.  
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Pharmacokinetics:  
Absorption: 
Ibuprofen is well absorbed after oral administration. Single doses of 200 mg taken on an 
empty stomach by volunteers produced peak serum levels after approximately 45 minutes. 
When taken after food, absorption was slower, peak levels appearing at 1.5 to 3 hours.  
 
Distribution:  
Apparent volume of distribution is 0.14 L/kg. Ibuprofen and its metabolites readily cross the 
placental barrier in pregnant rabbits and rats. It is not known if the drug enters the CSF or is 
excreted in breast milk.  
 
Protein Binding:  
99% of ibuprofen is protein bound. The high protein binding of the drug should be borne in 
mind when prescribing ibuprofen together with other protein bound drugs which bind to the 
same site on human serum albumin.  
Metabolism and excretion: 
Metabolism 
About 90% of ibuprofen is metabolised to two major metabolites (A and B); these are as 
follows: metabolite A (+) 2-4-(2-hydroxy-2-methylpropylphenyl) propionic acid, metabolite 
B (+) 2-4-(2-carboxypropylphenyl) propionic acid. Both metabolites are dextrorotatory and 
are devoid of anti-inflammatory and analgesic activity. 
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Normal volunteers and patients with rheumatoid arthritis were given ibuprofen 800 mg 
(immediate release tablet) as a single dose. After 14 to 24 hours the plasma levels of 
ibuprofen and metabolites were less than 0.25 microgram/mL. 
Excretion 
The kidney is the major route of excretion. In research done with immediate release 
formulation, 95% of ibuprofen was excreted in the urine within 24 hours of a single dose of 
500 mg; 35% as metabolite A (15 % free, 20% conjugated), 51% as metabolite B (42% free, 
9% conjugated), ibuprofen 9% (1% free, 8% conjugated). 
Table5. 2: Pharmacokinetics – Pharmacodynamics parameters of Ibuprofen 
Parameters Data 
Tmax  2 hrs 
Bioavailability 49–73% 
VD 0.14 L/kg 
Biological half life 1.8–2 hours 
Site and Mechanism of absorption Oral absorption 
Serum protein binding Highly serum protein bound (99%) 
Route of metabolism Rapidly metabolized in liver 
Metabolites Two metabolites, 2-[4-(2-hydroxy-2-
methylpropyl) phenyl] propionic acid 
(metabolite A) and 2-[4-(2-
carboxypropyl) phenyl] propionic acid 
(metabolite B), were found in rat, baboon 
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and human plasma, but not in dog 
plasma. Both metabolites were found in 
the urines of all four species, but there 
were marked differences in proportions 
and extent of conjugation. 
Activity of metabolites Have very little or no activity 
Route of excretion  The kidney is the major route of 
excretion. 95% of the drug was excreted 
in the urine within 24 hours of a single 
dose of 500 mg, 35% as metabolite A 
(15% free, 20% conjugated); 51% as 
metabolite B (42% free, 9% conjugated); 
ibuprofen 9% (1% free, 8% conjugated). 
Route of administration Oral 
Indications Rheumatoid arthritis, Osteoarthritis,  
Juvenile rheumatoid arthritis, 
Primary dysmenorrhea, Pyrexia. 
Brufen is also indicated for the relief of 
acute and/or chronic pain states in which 
there is an inflammatory component. 
Adverse effects Symptoms of overdose include nausea, 
abdominal pain and vomiting, dizziness, 
convulsion and rarely loss of 
consciousness. 
 
Ibuprofen Sustained Release Tablets                 DRUG PROFILE 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 62 
 
INDICATIONS 
• Rheumatoid arthritis 
• Osteoarthritis 
• Juvenile rheumatoid arthritis 
• Primary dysmenorrhoea 
• Pyrexia 
• Brufen is also indicated for the relief of acute and/or chronic pain states in which 
there is an inflammatory component. 
CONTRAINDICATIONS 
Known hypersensitivity to ibuprofen or any of the inactive ingredients. Hypersensitivity (e.g. 
asthma, rhinitis or urticaria) to aspirin or other nonsteroidal anti-inflammatory drugs. 
Ibuprofen should not be used in active gastrointestinal bleeding or perforation, related to 
previous NSAID therapy. Ibuprofen should not be used in patients with active, or a history of, 
ulcerative colitis, Cohn’s disease, recurrent peptic ulceration or gastrointestinal hemorrhage 
(defined as two or more distinct episodes of proven ulceration or bleeding). 
• Ibuprofen is contraindicated in patients with severe liver failure. 
• Ibuprofen is contraindicated in patients with severe renal failure (glomerular filtration 
below 30 ml/min). 
• Ibuprofen should not be given to patients with conditions involving an increased 
tendency to bleeding. 
• Ibuprofen is contraindicated during the third trimester of pregnancy. 
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Drug Interactions with Ibuprofen: 
DRUG INTERACTIONS:  
Ibuprofen is associated with several suspected or probable interactions that can 
affect the action of other drugs.  
ACE-inhibitors  
NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should 
be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. 
Aspirin  
When ibuprofen is administered with aspirin, its protein binding is reduced, although the 
clearance of free ibuprofen is not altered. The clinical significance of this interaction is not 
known; however, as with other NSAIDs, concomitant administration of ibuprofen and aspirin 
is not generally recommended because of the potential of increased adverse effects. 
Furosemide  
Clinical studies, as well as post marketing observations, have shown that ibuprofen can 
reduce the natriuretic effect of furosemide and thiazides in some patients. This response has 
been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy 
with NSAIDs, the patient should be observed closely for signs of renal failure as well as to 
assure diuretic efficacy. 
H-2 Antagonists  
In studies with human volunteers,   co -administration of cimetidine or ranitidine with 
ibuprofen had no substantive effect on ibuprofen serum concentrations. 
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Lithium  
NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium 
clearance. The mean minimum lithium concentration increased 15% and the renal clearance 
was decreased by approximately 20%. These effects have been attributed to inhibition of 
renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are 
administered concurrently, patients should be observed carefully for signs of lithium toxicity. 
Methotrexate  
NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit 
kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution 
should be used when NSAIDs are administered concomitantly with methotrexate. 
Warfarin  
Individuals taking oral blood thinners or anticoagulants [for example, warfarin (Coumadin)] 
should avoid ibuprofen because ibuprofen also thins the blood, and excessive blood thinning 
may lead to bleeding.  
Cardiac Glycosides 
NSAIDs may exacerbate cardiac failure, reduce glomerular filtration rate and increase plasma 
cardiac glycoside levels. Care should therefore be taken in patients treated with cardiac 
glycosides. 
Herbal Extracts: 
Ginkgo biloba may potentiate the risk of bleeding with NSAIDs. 
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ADVERSE REACTIONS 
Hypersensitivity 
Hypersensitivity reactions have been reported following treatment with ibuprofen. These may 
consist of (a) non-specific allergic reaction and anaphylaxis, (b) respiratory tract reactivity 
comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin 
disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, very 
rarely, bullous dermatoses (including Stevens-Johnson syndrome, toxic epidermal necrolysis 
and erythema multiforme). 
Gastrointestinal 
The most commontly observed adverse events are gastrointestinal in nature. Nausea, 
vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, 
haematemesis, ulcerative stomatitis and gastrointestinal haemorrhage and exacerbation of 
colitis and Crohn’s disease (see Contraindications section) have been reported following 
ibuprofen administration. Pancreatitis has been reported very rarely. 
Less frequently, gastritis, duodenal ulcer, gastric ulcer and gastrointestinal perforation have 
been observed. 
Cardiovascular 
Oedema has been reported in association with ibuprofen treatment. 
Other adverse events reported less commonly and for which causality has not 
necessarily been established includes: 
Renal nephrotoxicity in various forms, including intersitial nephritis, nephrotic syndrome and 
renal failure. 
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Hepatic 
Abnormal liver function, hepatic failure, hepatitis and jaundice. 
Neurological and special senses 
Visual disturbances, visual impairment, toxic neuropathy, optic neuritis, headaches, 
paraesthesia, anxiety, depression, insomnia, confusion, hallucinations, tinnitus, hearing 
impaired, vertigo, dizziness, malaise, fatigue and drowziness. 
Haematological 
Thrombocytopenia, leucopenia, neutropenia, agranulocytosis, aplastic anaemia and 
haemolytic anaemia. 
Dermatological 
Photosensitivity (see Hypersensitivity for other skin reactions) 
General 
Decreased appetite, fatigue. 
DOSAGE AND ADMINISTRATION 
These tablets are not capable of providing a divided dose. Do not halve the tablets. 
After assessing risk/benefit ratio in each individual patient, the lowest effective dose for the 
shortest duration should be used. 
Adult 
The recommended daily dosage is two Brufen SR tablets taken as a single dose, preferably in 
the early evening. The tablets should be swallowed whole with plenty of fluids. 
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In severe or acute conditions, the total daily dosage may be increased to three tablets taken as 
two tablets in the early evening and an additional tablet in the morning. 
Children 
Brufen SR is not recommended for children under 12 years. 
Maintenance dose 
In all indications the dose should be adjusted for each patient and the smallest dose that 
results in acceptable control of the symptoms employed. In general, patients with rheumatoid 
arthritis and osteoarthritis tend to require higher doses than patients with other conditions. 
Geriatric 
In elderly patients receiving 600 - 1,200 mg daily ibuprofen appeared to be well altered. 
However, since elderly patients may have a degree of impaired liver or renal function the 
adult dosage should be used with caution. 
OVERDOSAGE 
Symptoms include nausea, abdominal pain and vomiting, dizziness, convulsion and rarely, 
loss of consciousness. 
Clinical features of overdose with ibuprofen which may result are depression of the central 
nervous system and the respiratory system. 
There is no specific antidote to ibuprofe
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5.2. POLYMERS  PROFILE: 
                                                                                                     (Rowe R C, 4th edition)             
5.2.1. HYDROXY PROPYL METHYL CELLULOSE 
Synonyms: Benecel, HPMC, Methocel, Hydroxy propyl methyl                                               
cellulose 
 
Molecular weight: 10,000-15,000 
Structure: 
                       
Description : slightly off-white to beige powder in appearance and                   
may be formed into granules. 
Color   : white to yellowish white 
Odour   : odorless or nearly odorless 
Taste   : bland taste 
Texture  : powder 
Acidity / Alkalinity : pH 5.5-8.0 for a 1%w/w aqueous solution. 
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Viscosity for 2 %( w/v) aqueous solution 4000mpas (Viscosity measured at 200ºC) 
 Solubility: 
  Soluble in cold water, forming a viscous colloidal solution, practically insoluble in 
mixtures of ethanol and dichloromethane, mixtures of alcohol and wate 
 
Functional category:   
          Coating agent, film former, and rate controlling polymer for sustained release, 
stabilizing agent, suspending agent and viscosity builder. 
Applications in pharmaceutical technology: 
High viscosity grades may be used to retard the release of drugs from a matrix at 
levels of 10-80%w/w in tablets and capsules. 
Stability and Storage:  
Stable between pH 3-11, should be stored in a well-closed container in a cool and dry 
place. 
Incompatibilities:  
Incompatible with some oxidizing agents such as hydrogen peroxide, potassium 
permanganate. 
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5.2.2 ETHYL CELLULOSE 
Nonproprietary Names: 
BP: Ethyl cellulose 
PhEur: Ethyl cellulose 
USP-NF: Ethyl cellulose 
Synonyms: Aquacoat ECD; Aqualon; Ashacel; E462; Ethocel; ethylcellulosum;Surelease. 
Chemical Name: Cellulose ethyl ether  
CAS Registry Number: [9004-57-3] 
Empirical Formula and Molecular Weight: Ethyl cellulose is partially ethoxylated. Ethyl 
cellulose with complete ethoxyl substitution (DS = 3) is C12H23O6 (C12H22O5)n C12H23O5 
where n can vary to provide a Wide variety of molecular weights. Ethyl cellulose, an ethyl 
ether of cellulose, is a long-chain polymer of b- anhydroglucose units joined together by 
acetal linkages. 
Structural Formula: 
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Functional Category: 
Coating agent, flavouring agent, tablet binder, tablet filler, viscosity increasing agent. 
Description: 
Ethyl cellulose is a tasteless, free-flowing, and white to light tan-colored powder. 
Color                      : white to light tan-colored powder 
Odor                    : odorless. 
Taste        : tasteless 
Texture       : powder  
Solubility:  
Ethyl cellulose is practically insoluble in glycerin, propylene glycol, and water. Ethyl 
cellulose that contains less than 46.5% of ethoxyl groups is freely soluble in chloroform, 
methyl acetate, and tetrahydrofuran, and in mixtures of aromatic hydrocarbons with ethanol 
(95%). Ethyl cellulose that contains not less than 46.5% of ethoxyl groups is freely soluble in 
chloroform, ethanol (95%), ethyl acetate, methanol, and toluene. 
Stability and Storage Conditions: 
Ethyl cellulose is a stable, slightly hygroscopic material. It is chemically resistant to alkalis, 
both dilute and concentrated, and to salt solutions, although it is more sensitive to acidic 
materials than are cellulose esters. Ethyl cellulose is subject to oxidative degradation in the 
presence of sunlight or UV light at elevated temperatures. This may be prevented by the use 
of antioxidant and chemical additives that absorb light in the 230–340nm range. Ethyl 
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cellulose should be stored at a temperature not exceeding 328ºC (908F) in a dry area away 
from all sources of heat. It should not be stored next to peroxides or other oxidizing agents. 
Incompatibilities: 
Incompatible with paraffin wax and microcrystalline wax. 
Applications in Pharmaceutical Formulation or Technology 
 Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. 
 The main use of ethyl cellulose in oral formulations is as a hydrophobic coating agent 
for tablets and granules. Ethyl cellulose coatings are used to modify the release of a 
drug, to mask an unpleasant taste, or to improve the stability of a formulation. For 
example where granules are coated with ethyl cellulose to inhibit oxidation. 
  Modified-release tablet formulations may also be Produced using ethyl cellulose as a 
matrix former. Ethyl cellulose, dissolved in an organic solvent or solvent mixture, can 
be used on its own to produce water-insoluble films. 
 Drug release through ethyl cellulose-coated dosage forms can be controlled by 
diffusion through the film coating. This can be a slow process unless a large surface 
area (e.g. pellets or granules compared with tablets) is utilized. In those instances, 
aqueous ethyl cellulose dispersions are generally used to coat granules or pellets. 
 Ethyl cellulose-coated beads and granules have also demonstrated the ability to 
absorb pressure and hence protect the coating from Fracture during compression.  
 High-viscosity grades of ethyl cellulose are used in drug microencapsulation.  
 Release of a drug from an ethyl cellulose microcapsule is a function of the 
microcapsule wall thickness and surface area. 
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  In tablet formulations, ethyl cellulose may additionally be employed as a binder, the 
ethyl cellulose being blended dry or wet granulated with a solvent such as ethanol 
(95%). 
 Ethyl cellulose produces hard tablets with low friability, although they may 
demonstrate poor dissolution. Ethyl cellulose has also been used as an agent for 
delivering therapeutic agents from oral (e.g. dental) appliances. 
 In topical formulations, ethyl cellulose is used as a thickening agent in creams, 
lotions, or gels, provided an appropriate solvent is used. Ethyl cellulose has been 
studied as a stabilizer for emulsions. Ethyl cellulose is additionally used in cosmetics 
and food products. 
Table 5.3: Uses of ethyl cellulose. 
Use Concentration (%) 
Microencapsulation 10.0–20.0 
Sustained-release tablet coating 3.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
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                                             5.2.3  LACTOSE MONOHYDRATE 
Synonyms       : Milk sugar; Pharmatose; Lactochem; Lactohale; Prismalac;Saccharum 
lactis 
Category     : Diluent for dry powder, tablet and capsule diluents 
ChemicalName: o-ß-D-Galactopyranosyl- (1→4) –α-D-glucopyranose    monohydrate                                                                                                
Empirical Formula : C12H22O11. H2O 
Molecular Weight : 360.31
 
      Description : It is a crystalline powder which is white to off white in color,            
odorless, weet tasting. 
Density  : 1.54 g/cm3 
Melting Point  : 201-202°C 
Moisture Content : It contains up to 1 % w/w water 
Stability  : Lactose may develop a brown coloration on storage 
Storage  : It is stored in well closed container in a cool and dry place 
Incompatibilities : Incompatible with amino acid, aminophyllines. 
Structure: 
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5.2.4 TALC 
Nonproprietary Names: 
• BP: Purified talc 
• JP: Talc 
• PhEur: Talcum 
• USP,Talc 
Synonyms: 
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore. 
Functional Category: 
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant 
Description: 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Solubility: 
Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
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Empirical Formula and Molecular Weight: 
Talc is a purified, hydrated, magnesium silicate, approximating to the formula 
Mg6(Si2O5)4(OH)4. It may contain small, variable amounts of aluminum silicate and 
iron. 
Specific gravity: 2.7–2.8 
Stability and Storage Conditions: 
Talc is a stable material and may be sterilized by heating at 160°C for not less 
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. Talc should be stored in a well-closed container in a cool, dry place. 
Safety:  
Talc is used mainly in tablet and capsule formulations. Talc is not absorbed 
systemically following oral ingestion Triethyl Citrate. 
Applications in Pharmaceutical Formulation or Technology: 
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent. 
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Table5.4: use of talc 
Use Concentration (%) 
Dusting powder 90.0–99.0 
Glidant and tablet lubricant 1.0–10.0 
Tablet and capsule diluent 5.0–30.0 
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5.2.5 MAGNESIUM STEARATE 
Nonproprietary Names: 
    BP  : Magnesium stearate 
    IP  : Magnesium stearate 
    PhEur : Magnesii stearas 
    USPNF : Magnesium stearate 
Synonyms: 
   Magnesium octadecanoate; octadecanoic acid; magnesium salt; stearic acid. 
Chemical Name :  
   Octadecanoic acid magnesium salt 
Empirical Formula: Mg(C18H35O2)2 
Molecular Weight: 591.27 g/mol 
Molecular structure:  
                                           
Functional Category: Tablet and capsule lubricant. 
 
 
Ibuprofen Sustained Release Tablets                 POLYMERS PROFILE 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 67 
 
Description: 
           Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic taste. The 
powder is greasy to the touch and readily adheres to the skin. 
Solubility:  
           Practically insoluble in ethanol (95%), ether and water; slightly soluble in warm 
benzene and warm ethanol (95%). 
Incompatibility:  
  Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium Stearate cannot be used in product containing aspirin, some 
vitamins and most alkaloidal salts. 
Storage conditions: 
  Should be stored in well-closed container, in a cool & dry place. 
Applications in Pharmaceutical Formulation or Technology: 
  Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams 
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5.2.6 Isopropyl alcohol 
Synonyms :  Di methyl carbinol,  isopropanol , 2-propanol. 
Empirical formula : C3 H8 O 
Molecular wt : Disinfectant,  solvent 
Description : Miscible with benzene, chloroform,   ethanol. 
   Soluble in acetone 
    insoluble   in salt solutions. 
Functional category      : Granulating agent 
 
 
Storage conditions    : Store in a airtight container in a cool & dry place 
Incompatibility    : Incompatible with H2O2 & Nitric acid.  Salting out             
from  aqueous preparations by adding sodium salts 
Applications     : Tablets - Film forming agent & Granulating agent 
70%v/v used as disinfectant, Not recommended for oral use 
  
 
 
        
Materials & 
Equipment’s 
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6.MATERIALS AND EQUIPMENTS 
 
Table 6.1: List of materials with source 
S.No. Name of Ingredients Name of supplier 
1 Ibuprofen Tristar formulation Pvt. Ltd., Puducherry. 
2 HPMC K100M Tristar formulation Pvt. Ltd., Puducherry. 
3 Ethyl cellulose Tristar formulation Pvt. Ltd., Puducherry. 
4 IPA Nickon laboratories Pvt. Ltd., Puducherry. 
5 Polyvinyl pyrrolidone  Nickon laboratories Pvt. Ltd., Puducherry. 
7 Magnesium stearate Loba chemie Pvt.Ltd., Mumbai. 
8 Talc Loba chemie Pvt.Ltd., Mumbai. 
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6.2 Equipments used: 
Table 6.2: List of equipments with model/make 
S.No. Equipment Model/ Make 
   1 Electronic balance Shimadzu BL-220H, Japan. 
   2 Bulk density apparatus Indolabs VTAP/MATIC-II, Chennai. 
   3 Standard sieves Jayant scientific, India. 
   4 Hot air oven Precision scientific Co., Chennai. 
   5 
Sixteen punch tablet compression 
machine 
Cadmach, Ahmadabad, India. 
  6 Friability apparatus Veego scientific VFT-DV, Mumbai. 
  7 Hardness tester Monsanto  pifzer 
  8 Vernier caliper Indolabs, Mitutoyo. 
  9 Humidity chamber Labtech, Ambala. 
 10 USP dissolution test apparatus Type I Veego scientific VDA-8DR, Mumbai. 
 11 UV spectrophotometer Elico-SL 159 UV-Visible 
spectrophotometer. 
 12 FTIR spectrophotometer Perkin elmer-Pharmaspec-1. 
 13 Differential scanning calorimeter Shimadzu DSC 60, Japan. 
  
 
 
 
 
 
 
 
 
 
 
 
Experimental 
Work 
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7.EXPERIMENTAL WORK 
 
7.1. PREFORMULATION STUDIES: 
7.1.1. Characterization of Ibuprofen: 
7.1.1.1. Organoleptic properties:  
(Lachman L, et al., 1991; Banker G.S., and Rhodes C.T., 2009) 
   The colour, odour and taste of the drug were recorded using descriptive 
terminology. 
7.1.1.2. IR spectrum interpretation:        
(IP, 2007; Silverstein R.M., Webster F.X., 2003) 
The infrared spectrum of pure Ibuprofen was recorded and spectral analysis 
was done. The dry sample of the drug was thoroughly mixed with potassium 
hydrobromide and directly placed in the sample holder. 
7.1.1. Loss on drying:                                                                                (IP., 2007) 
  Loss on drying is the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
condition. The test can be carried out on the well mixed sample of the substance. 
                      Initial weight of substance – Final weight of substance 
  Loss on drying = --------------------------------------------------------------------       x 100 
 Initial weight of substance 
 
7.1.1.4. Melting point:                                                                                 (IP, 2007) 
  Melting point of the drug was determined by capillary tube method. 
 
Ibuprofen sustained Release Tablets      EXPERIMENTAL WORK                
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 84 
7.1.1.5. Solubility study:                                                                         (IP, 2007) 
 The solubility of drug was recorded by using various descriptive terminology 
specified in Indian Pharmacopoeia, 2007.  
7.1.2. Analytical methods:  
7.1.2.1. Determination of λ max:                                                            (IP., 2007) 
Preparation of stock solution:  
 50 mg of Ibuprofen was accurately weighed and transferred to a 50 ml 
volumetric flask. It was dissolved in sufficient amount of Methanol and volume was 
made upto 50 ml with Methanol. Exactly 10ml of the stock solution was pipetted out 
and was diluted to 100 ml with Methanol (10 µg/ml). The spectrum was recorded in 
the range of 220-370 nm.  
Preparation of standard curve of Ibuprofen:                                           (IP, 2007) 
i. By using in 0.1N hydrochloric acid: 
   A standard curve was prepared by dissolving 50 mg of Ibuprofen 50 ml 
of   0.1N HCl. In the stock solution 1 ml withdrawn and diluted to 25 ml of 0.1N HCl 
. It was further diluted with 0.1N HCl to get the solution in the concentration range of 
0-20 µg/ml. The absorbance values were determined at 272.5 nm. 
ii. By  using in phosphate buffer pH
 
 7.4:  
    A standard curve was prepared by dissolving 50 mg of Ibuprofen in 
methanol and shake upto drug dissolved, then finally make upto 50 ml with pH 7.4 
phosphate buffer. In the stock solution 1 ml withdrawn and diluted to 25 ml with 
phosphate buffer. It was further diluted to get the solution in the concentration range 
0-20µg/ml. The absorbance values were determined at 274 nm.  
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7.1.3. Compatibility testing of drug with polymer: (IP, 2007; Aulton M.E., 2007; 
Silverstein R.M, Webster F.X., 2003; Skoog D.A.,et.al.,1996) 
 The proper design and formulation of a dosage form requires consideration of 
the physical, chemical and biological characteristics of all drug substances and 
excipients to be used in the fabricating the product. Each polymer used in the 
formulations was blended with the drug levels that are realistic with respect to the 
final dosage form. Each polymer was thoroughly blended with drug to increase drug - 
polymer molecular contacts to accelerate the reactions if possible. 
 
7.1.3.  Fourier transform Infra-Red (FTIR) spectroscopy:  
  FTIR study was carried out to check compatibility of drug with polymers. 
Infrared spectrum of Ibuprofen was determined on Fourier transform Infrared 
Spectrophotometer using KBr dispersion method. The base line correction was done 
using dried potassium bromide. Then the spectrum of dried mixture of drug and 
potassium bromide was run followed by drug with various polymers by using FTIR 
spectrophotometer. The absorption maximums in spectrum obtained with the 
substance being examined correspond in position and relative intensity to those in the 
reference spectrum.  
7.1.4.  Differential scanning calorimetry (DSC): 
 Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC study was performed on pure drug, and polymers, drug+HPMC K15M, 
drug+Carboxy methylcellulose and drug+ Xathan gum. The study was carried out 
using a Shimadzu. The 2 mg of sample were heated in a hermetically sealed 
aluminum pans in the temperature range of 25-300ºC at heating rate of 10ºC /min 
under nitrogen flow of 30ml/min.  
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7.1.5. Formulation of Ibuprofen sustained release matrix tablets:  
                                    (Sharma A., et al., 2009; Bandhalarajan S., et al., 2011) 
Table 7.1: Composition of Ibuprofen matrix tablets 
Ingredients(mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Ibuprofen 200 200 200 200 200 200 200 200 200 
HPMC K100M  40 80 120 - - - - - - 
Ethyl cellulose - - - 40 80 120 - - - 
HPMC+EC  - - - - - - 40 80 120 
IPA+PVP q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Lactose 150 110 70 150 110 70 150 110 70 
Magnesium stearate 5 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 5 
Total weight 400 400 400 400 400 400 400 400 400 
 
7.1.5. Preparation of granules:                                               (Prema R., et al., 2010) 
           Granules for Ibuprofen matrix tablets were prepared by wet granulation 
technique using various percentages of HPMC K15M, carboxy methyl cellulose and 
xanthan gum as release retardant polymers. All the powders passed through sieve 
No.80. The required quantity of drug, various polymers and other ingredients were 
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mixed thoroughly and a sufficient volume of granulating agent (isopropyl alcoholic 
solution of polyvinyl pyrrolidone) was added slowly. After enough cohesiveness was 
obtained, the wet mass was sieved through sieve No.8. The granules were dried at 
60 C for 30 minutes and then the dried granules were passed through sieve No.16.  
Talc and magnesium stearate were finally added as a glidant and lubricant 
respectively.   
7.1.6. Evaluation of granules: 
7.1.6.1. Angle of repose:                                                 (Subramanyam C.V.S., 2009) 
The angle of repose of granules was determined by the funnel method. The 
accurately weighed granules were taken in a funnel. The height of the funnel was 
adjusted in such a way that the tip of the funnel just touched the apex of the heap of 
the granules. The granules were allowed to flow through the funnel freely onto the 
surface. The diameter of the granules cone was measured and angle of repose was 
calculated using the following equation. 
   tan   = h/r 
Where, h and r are the height and radius of the granules cone respectively.       
                      Table 7.2: Standard values of angle of repose ( )  
S. No. Flowability Angle of repose 
1 Excellent <25 
2 Good 25-30 
3 Passable* 30-40 
4 Poor 37-45 
5 Very poor >45 
* Adding Glidant for improving flow 
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7.1.6.2. Loose bulk density:                                          (Raghuram R. K., et al., 2003)                          
An accurately weighed granules from each formulation was lightly shaken to 
break any agglomerates formed and it was introduced in to a measuring cylinder. The 
volume occupied by the granules was measured which gave bulk volume. The loose 
bulk density of granules was determined using the following formula.  
Loose bulk density = Total weight of granules / Total volume of granules 
7.1.6.3. Tapped bulk density:                                        (Raghuram R.K., et al., 2003)                                                
An accurately weighed granules from each formula was lightly shaken to 
break any agglomerates formed and it was introduced into a measuring cylinder. The 
measuring cylinder was tapped until no further change in volume was noted which 
gave the tapped volume. The TBD of granules was determined by the following 
formula.  
Tapped bulk density =   Total weight of granules/ Tapped volume                                 
7.1.6.4. Hausner ratio:                                                                   (Aulton M.E., 2007) 
Hausner ratio is the ratio between tapped density and bulk density. Hausner 
ratio less than 1.25 indicates good flow properties while Hausner ratio greater than 
1.25 shows poor flow of granules. 
7.1.6.5. Carr’s compressibility index:                                           (Aulton M.E., 2007)                    
  It is a simple index that can be determined on small quantities of granules. In 
theory, the less compressible a material the more flowable it is.  
             The compressibility index of the granules was determined using following 
formula.    
 Carr’s compressibility index (%)   = [(TBD-LBD)/ TBD] ×100     
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Table 7.3: Standard values of carr’s index 
Carr’s index % Flowability 
5-15 Excellent 
12-16 Good 
18-21 Fairly acceptable 
23-35 Poor 
33-38 Very poor 
< 40 Very very poor 
                                     
7.2. Preparation of tablets:                                         (Bandhalarajan S., et al., 2011) 
            The evaluation of granules showed excellent flow properties. The granules 
were compressed into tablets on 16 station rotary tablet compression machine using 
11 mm round, biconcave punches. The compressed tablets were evaluated for various 
parameters viz. appearance, thickness, diameter, hardness, friability, weight variation, 
drug content and in vitro drug release studies.  
7.3. Evaluation of Sustained release matrix tablet of Ibuprofen:       
7.3.1. Appearance:       
                                    (Lachman L., et al., 1991; Bankar G.S. and Rhodes C.T., 2009) 
The tablets were visually observed for capping, chipping, and lamination. 
7.3.2. Dimension (thickness and diameter):                    (Lachman L., et al., 1991) 
The thickness and diameter of tablets were important for uniformity of tablet 
size. The thickness and diameter of the tablets was determined using a vernier caliper. 
Ten tablets from each type of formulation were used and average values were 
calculated. 
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7.3.3. Weight variation test:                         (IP, 2007) 
For weight variation, 20 tablets of each type of formulation were weighed 
individually on an electronic balance, average weight was calculated and individual 
tablet weight was then compared with the average value to find out the deviation in 
weight. 
Table 7.4: Specifications of %Weight variation allowed in tablets as per IP. 
S. No Average Weight of tablet % Deviation 
1. 80 mg or less 10 
2 More than 80 but less than 250 mg 7.5 
3 250 mg or more 5 
 
 
7.3.4. Hardness:  
  For each type of formulation, the hardness value of 10 tablets was determined 
using Monsanto hardness tester.  
7.3.5. Percentage friability :                                 
                        (Lachman L., et al., 1991; Banker G.S. and Rhodes C.T., 2009) 
Friability is the measure of tablet strength. This test subjects a number of 
tablets to the combined effect of shock abrasion by utilizing a plastic chamber which 
revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of preweighed tablets was placed in Roche friabilator which was 
then operated for 100 revolutions. The tablets were then dedusted and reweighed. A 
loss of less than 1 % in weight is generally considered acceptable. Percent friability 
(% F) was calculated as follows, 
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7.3.6. Content uniformity:       
                                                           (Krishna R. Gupta, et al., 2011; IP, 2007) 
  Content uniformity was determined by accurately weighing 20 tablets and 
crushing them in mortar with the help of a pestle. Then an accurately weighed 
quantity of powder equivalent to 25 mg of drug was transferred to a 50 ml volumetric 
flask. Then added few ml of methanol and made upto 50ml with methanol. The 
solution was filtered through whatmann filter paper. 5 ml of the filtrate was diluted to 
50 ml with Methanol. Then   3 ml of the resulting solution was again diluted to 10 ml 
with Methanol. The absorbance of the resulting 15 µg/ml solution was recorded at 
274nm. 
7.3.7. In-vitro dissolution studies:  
                    (IP, 2007; Bandhalarajan S., et al., 2011;Yeole P.G., et al., 2006) 
The in-vitro dissolution studies were performed using USP type I dissolution 
apparatus at 50rpm. Dissolution test was carried out for a total period of 8 hours using 
0.1N HCl (pH 1.2) solution (900 ml) as dissolution medium at 37 ± 0.5° for first 2 h, 
and pH 7.4 phosphate buffer solution (900 ml) for the rest of the period An aliquot 
(5ml) was withdrawn at specific time intervals and absorbance was determined by 
U.V. spectrophotometer at 274nm. The release studies were conducted in triplicate. 
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7.3.8. Data Analysis (Curve Fitting Analysis): 
                    (Brahmankar D.M and Jaiswal S.B., 2009; Chandira, et al., 2009) 
  To analyze the mechanism of the drug release rate kinetics of the dosage form, 
the data obtained were graphed as: 
i. Cumulative percentage drug released Vs Time (In-vitro drug release plots) 
ii. Cumulative percentage drug released Vs Square root of time (Higuchi’s plots) 
iii. Log cumulative percentage drug remaining Vs Time (First order plots) 
iv. Log percentage drug released Vs Log time (Peppas plots) 
Higuchi release model: 
 To study the Higuchi release kinetics, the release rate data was fitted to the 
following equation.    F = K.t ½ 
Where,  ‘F’ is the amount of drug release, 
‘K’ is the release rate constant, and ‘t’ is the release time. 
When the data is plotted as accumulative drug released versus square root of time, 
yields a straight line, indicating that the drug was released by diffusion mechanism. 
The slope is equal to ‘K’. 
Korsmeyer and Peppas release model: 
  The release rate data were fitted to the following equation, 
Mt / M∞   = K. tn 
  Where,   Mt / M∞ is the fraction of drug release,  
      ‘K’ is the release constant, 
      ‘t’ is the release time, 
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  ‘n’ is the diffusional exponent for the drug release that dependent on the shape 
of the matrix dosage form. 
  When the data is plotted as Log of released versus Log time, yields as straight 
line with a slope equal to ‘n’ and the ‘K’ can be obtained from Y – intercept. 
  For non- Fickian release the ‘n’ values falls between 0.5 and 1.0 while for 
Fickian (case I) diffusion n= 0.5 and zero order release ( case II transport) n= 1.0. 
Zero order release rate kinetics: 
  To study the zero-order release kinetics the release rate data are fitted to the 
following equation. 
F = Kt 
     Where ‘F’ is the fraction of drug release, 
      ‘K’ is the release rate constant and  
      ‘t’ is the release time. 
  When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys zero-order release kinetics, with a slope equal to K.  
7.4. Stability study:           
                                   (Carstensen J. T., et al., 2008; Manavalan R, et al., 2008)  
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted.  
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ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25 C ± 2 C at 60% RH ± 5% for 12 Months  
 Accelerated Testing: 40 C ± 2 C at 75% RH ± 5% for 6 Months  
In present study the selected formulation F9 exposure  up to 3 months stability 
studies at accelerated condition (40 C ± 2 C
 
at 75% RH ± 5% RH) to find out the 
effect of aging on hardness, drug content and in vitro drug release.  
Stability studies were carried out at accelerated condition (40 C ± 2 C
 
at 75% 
RH ± 5% RH) for the optimized formulation F9. The matrix tablets were stored at 
40 C ± 2 C at 75% RH ± 5% RH for accelerated temperature in closely packed with 
aluminium foil for 3 months. The samples were withdrawn after periods of 1st month, 
2nd month and 3rd month. The samples were analyzed for its hardness, drug content 
and in vitro drug release.    
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7. RESULTS AND DISCUSSION 
 
8.1. Pre-formulation Parameters: 
8.1.1. Characterization of Ibuprofen: 
8.1.1.1. Organoleptic properties: 
White or almost white colored crystalline powder. 
 
Figure 8.1: IR spectra of Ibuprofen 
8.1.1.3. Loss on drying: 
            The percentage loss on drying for Ibuprofen was found to be 0.1%. 
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 Melting point: 
Melting point values of Ibuprofen sample was found to be 86°C, 75°C and 76°C. The 
reported melting point Average for Ibuprofen is 76°C. Hence, experimental values are 
in good agreement with official values 
λmax Determination: 
λmax Determination in 0.1N HCl: 
The absorption maximum for Ibuprofen was found to be 220.5 nm. 
 
 
Figure 8.2:  λ max observed for Ibuprofen in 0.1NHCl 
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8.1.2.2. λmax Determination in Phosphate buffer pH  7.4:  
  The absorption maximum for Ibuprofen was found to be 222 nm. 
 
Figure 8.3:  λ max observed for Ibuprofen in Phosphate buffer pH 7.4 
8.1.2.3. Preparation of standard curve of Ibuprofen: 
i. By using in 0.1N HCl: 
UV absorption spectrum of Ibuprofen in 0.1N HCl shows λ max at 220.5 
nm. Absorbance obtained for various concentrations of Ibuprofen 0.1N HCl in are 
given in table 8.1. The graph of absorbance vs. concentration for Ibuprofen was 
found to be linear in the concentration range of 0 – 20 μg /ml.  
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Table 8.1: Data of concentration and absorbance for Ibuprofen in 0.1N HCl 
 
S.No. Conc (µg/ml) Absorbance 
1 0 0 
2 2 0.0932 
3 4 0.1865 
4 6 0.2797 
5 8 0.373 
6 10 0.4662 
 
 
 
Figure 8.4: Calibration Curve of Ibuprofen in 0.1N HCl 
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Table 8.2:  Data for Calibration Curve Parameter of 0.1N HCl 
 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope  0.01529 
3 Intercept 0.00024 
ii. By using in Phosphate buffer pH 7.4: 
 
UV absorption spectrum of Ibuprofen in Phosphate buffer pH 7.4 
shows λ max at 222 nm. Absorbance obtained from various concentrations of 
Ibuprofen Phosphate buffer pH 7.4 is are given in table 8.3. The graph of absorbance 
vs concentration for Ibuprofen was found to be linear in the concentration range of 0 – 
20 μg/ml. 
Table 8.3: Concentration and absorbance for Ibuprofen in Phosphate buffer pH 7.4 
                
 
 
 
 
 
S. No. Concentration (µg/ml) Absorbance 
1 0 0.000 
2 4 0.146 
3 8 0.291 
4 12 0.432 
5 16 0.575 
6 20 0.715 
Ibuprofen sustained Release Tablets      RESULTS AND DISCUSSION                
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 100 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 5 10 15 20 25
A
bs
o
rb
a
n
c
e
 
Concentration(µg/ml)
Calibration Curve
 
Figure 8.5: Calibration curve of Ibuprofen in Phosphate buffer pH  
       Table 8.4:  Data for Calibration Curve Parameter of Phosphate buffer PH 7.4  
 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope  0.03574 
3 Intercept 0.00248 
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8.1.2.4. Percentage purity of pure Drug: 
The percentage purity of drug was calculated by using calibration graph 
method (least square method). 
Table 8.5:  Percentage purity of pure drug 
 
The reported percentage purity for Ibuprofen is 99 to 101% (Indian 
Pharmacopoeia 2007). 
 
 
 
S.No. Percentage purity (%) Avg. percentage purity (%) 
1 98.32  
99.69±1.21 2 100.16 
3 100.60 
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8.1.3. Compatibility testing of drug with polymer: 
8.1.3.1. Fourier transform Infra-Red (FTIR) spectra’s: Figure  
 
Figure 8.6: IR spectra of Ibuprofen and Ethyl cellulose 
 
           Figure 8.7: IR spectra of Ibuprofen and HPMCK100M  
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FTIR spectroscopy was used to ensure that no chemical interaction between 
the drugs and polymers had occurred. From the FTIR spectral Figures  to 8.6 to 8.7 
interpretations the following result was obtained. The FTIR of Ibuprofen and 
combination of polymers shows intense band in the table as follows. 
Table 8.6: IR peaks of functional groups (cm-1) 
Sr. 
No 
Name of the 
ingredient -C = O -COOH -NH -OH 
1. Ibuprofen 3452.08      2955.4 1183.53 668.03 
2. Ibuprofen and HPMC K100M 3461.76 1230.5 779.48 668.60 
3. Ibuprofen and  EC 3452.25  2956.37 1230.50 663.10 
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8.1.3.2 Differential  Scanning  Caiorimetry(DSC): 
The compatibility and interactions between drugs and polymer were checked 
using DSC, results obtained were shown in Figure 7.8 to 7.10   .       
 
Fig ;8.8    Differential  scanning  calorimetry  analysis  of  ibuprofin 
 
                          
F ig:8.9 Differntial  scanning  calorimetry  analysis of  ibuprofin and   
               HPMCK100M 
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Fig 8.10  Differential  scanning calorimetry  analysis of ibuprofin and    
ethylcellulose 
 
Table 8.7 :  Data of DSC thermogram parameters 
  DSC thermogram showed that there was no any major difference in onset 
temperature and peak temperature, when compared with pure drug’s thermogram 
interaction was found between drug and polymers. 
 
 
S.No. Name of ingredients and physical   mixtures 
used in formulation 
Temperature at which peak 
obtained 
1. Ibuprofen 76.33ºC 
2. Ibuprofen  and HPMC K100M 76.24ºC 
3. Ibuprofen  and  EC                   72.68ºC 
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8.2. Evaluation of blended granules: 
The blended granules of different formulation were evaluated for angle of 
repose, loose bulk density, tapped bulk density, compressibility index and Hausner 
ratio. The results of these evaluations were as follows: - 
8.2.1. Angle of repose: 
            Angle of repose ranged from 28.3±0.92 to 37.4±0.06. The results were found 
to be below 30o and hence the blend was found to have good flowability. (Table 7.9) 
8.2.2. Loose bulk density and tapped density: 
            Bulk and tapped densities are used for the measurement of Compressibility 
index.  (Table 7.7).  
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Table 8.8: Flow properties of granules 
F. 
code 
Angle of 
repose (o)* 
Loose bulk 
density 
(g/ml)* 
Tapped bulk 
density 
(g/ml)* 
Carr’s 
index (%)* 
Hausner’s 
ratio* 
F1 30.16±0.04 0.261±0.19 0.296±0.19 9.717±0.22 5.44 ±0.19 
F2 37.43±0.06 0.525±0.528 0.359±0.242 8.448±0.93 4.76 ±1.22 
F3 32.2.±1.57 0.504±0.518 0.333±0.226 8.902±1.2 5.01 ±1.21 
F4 28.7±0.72 0.568±0.509 0.449±0.305 10.38±0.82 5.73±1.31 
F5 30.2±1.76 0.616±0.506 0.531±0.361 10.01±0.64 5.49±0.68 
F6 29.3±1.67 0.549±0.538 0.389±0.264 9.455±0.87 5.24±1.34 
F7 29.0±0.62 0.537±0.557 0.350±0.236 9.072±0.94 5.06±1.25 
F8 28.3±0.92 0.547±0.518 0.412±0.281 10.28±0.56 5.68±0.82 
F9 29.3±1.32 0.555±0.516 0.404±0.272 9.167±0.59 5.26±1.26 
*All the values are expressed as mean± SD, n=3. 
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8.2.3. Compressibility index (Carr’s index): 
 The compressibility index (%) ranged from 8.44±0.93 to 10.38±0.82.  (Table 
8.7). The blend was found to have excellent flowing property as the result were found 
to be below 15%.  
8.2.4. Hausner ratio: 
The Hausner ratio ranged from 4.76±1.22 to 5.73±1.31 (Table 7.8). The result 
indicates the free flowing properties of the granules. 
8.3. Evaluation of sustained release matrix tablets: 
8.3.1. Appearance: 
The tablets were observed visually and did not show any defect such as 
capping, chipping and lamination. 
8.3.2. Physical characteristics:    
The physical characteristic of  Ibuprofen sustained release matrix tablets         
(F1 to F9) such as thickness, diameter, hardness, friability, weight variation and drug 
content were determined and results of the formulations (F1 to F9) found to be within 
the limits specified in official books.  
8.3.3. Dimension (Thickness and Diameter): 
Thickness and diameter specifications may be set on an individual product 
basis. Excessive variation in the tablet thickness and diameter can result in problems 
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with packaging as well as consumer acceptance. The size (diameter) of the tablets of 
all formulations was found to be 4.27±0.06 to 4.60±0.06 mm. 
8.3.4. Tablet Hardness:  
A difference in tablet hardness reflects difference in tablet density and 
porosity. In which turn are supposed to result in different release pattern of the drug 
by affecting the rate of penetration of dissolution fluid at the surface of the tablet and 
formation of gel barrier. The hardness of tablets was found to be in the range of 
6.32±0.05  kg/cm2 to 6.75±0.01kg/cm2. This indicates good tablet strength.  
8.3.5. Percent Friability: 
Percentage friability of all the formulations was found between 0.414±0.02 to 
0.679±0.01%. This indicated good handling property of the prepared SR tablet. 
8.3.6. Weight Variation: 
A tablet is designed to contain a specific amount of drug. When the average 
mass of the tablet is 400 mg the pharmacopoeial limit for percentage deviation is 
±5%. The percentage deviation from average tablet weight for all the tablet was found 
to be within the specified limits and hence all formulations complied with the test for 
weight variation according to the pharmacopeial specifications. 
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Table 8.9: Physico-Chemical Characterization of Ibuprofen SR Tablets 
F. 
Code 
Thickness 
(mm)* Hardness (kg/cm2)* 
Friability 
(%) 
Weight 
variation 
(mg) 
Drug 
content 
(%w/w)** 
F1 4.44±0.02    6.32±0.05 0.679±0.01 398.25±.139 99.83±0.69 
F2 4.37±0.06 6.65±0.01 0.503±0.04 397.25±2.39 99.59±1.05 
F3 4.40±0.09 6.75±0.03 0.417±0.02 397.65±1.94 98.95±0.87 
F4 4.38±0.07 6.46±0.01 0.568±0.06 395.05±1.75 99.72±0.87 
F5  4.54±0.02 6.54±0.03 0.515±0.03 397.05±1.94 99.65±0.66 
F6 4.27±0.06 6.74±0.02 0.667±0.03 396.75±2.04 99.61±0.65 
F7 4.60±0.06 6.36±0.01 0.655±0.02 396.55±1.75 98.86±1.55 
F8 4.27±0.05 6.74±0.01 0.601±0.01 398.09±1.94 97.55±0.42 
F9 4.32±0.06 6.85±0.03 0.414±0.02 398.55±2.04 99.98±0.63 
*All the values are expressed as mean± SD, n=3 
7.3.7. Drug content of Ibuprofen: 
The content of active ingredients in the formulation was found to be between 97.55 
±0.42 to99.98 ± 0.65% w/w, which is within the specified limit as per Indian 
Pharmacopoeia 1996 (i.e. 90-110% w/w). 
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Table 8.10: Invitro dissolution studies 
 
S.No 
Time 
(h) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 1 
8.91± 
0.92 
8.97± 
0.66 
9.23± 
0.99 
9.29± 
0.98 
9.38± 
1.35 
8.99± 
0.67 
9.66± 
1.02 
9.58± 
0.85 
9.72± 
0.56 
2 2 
15.2± 
1.20 
29.2± 
1.90 
22.4± 
0.07 
29.3± 
0.55 
28.4± 
0.59 
29.6± 
0.12 
28.9± 
0.93 
29.2± 
0.69 
30.1± 
0.32 
3 3 
39.9± 
0.98 
36.7± 
0.99 
38.7± 
0.58 
39.4± 
0.21 
40.2± 
1.11 
36.8± 
0.54 
37.1± 
0.66 
39.9± 
0.78 
38.4± 
0.35 
4 4 
57.9± 
0.63 
55.2± 
1.06 
46.4± 
1.8 
49.2± 
0.58 
53.2± 
1.08 
49.0± 
0.88 
44.2± 
0.66 
58.5± 
0.90 
45.6± 
0.69 
5 5 
75.5± 
0.48 
82.4± 
0.98 
59.8± 
0.69 
69.9± 
1.96 
67.1± 
0.36 
59.2± 
0.96 
55.3± 
0.23 
67.2± 
0.26 
59.2± 
0.99 
6 6 
93± 
0.89 
92± 
0.35 
72.1± 
1.50 
81.4± 
1.26 
74.6± 
0.81 
68.6± 
1.21 
69.8± 
0.62 
71.6± 
0.59 
64.7± 
0.56 
7 7 93.2± 92.3± 93.1± 90.1± 87.3± 77.1± 79.9± 80.4± 70.9± 
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0.42 0.30 0.53 0.59 0.48 1.20 0.65 1.96 0.51 
8 8 
93.4± 
0.26 
92.5± 
0.28 
93.4± 
0.09 
90.2± 
0.56 
93± 
0.32 
80.9± 
1.3 
94± 
0.61 
89.2± 
1.31 
77.2± 
1.56 
9 9 
93.6± 
0.23 
92.8± 
0.20 
93.6± 
0.05 
90.5± 
0.65 
93.5± 
1.23 
95± 
0.59 
94.7± 
0.54 
95± 
0.66 
88.6± 
1.2 
10 
10 
 
93.7± 
0.25 
92.9± 
0.66 
93.9± 
0.64 
90.8± 
0.07 
93.9± 
0.09 
95.8± 
0.26 
94.9± 
0.15 
95.6± 
0.35 
96.2± 
0.65 
8.3.8InvitroDissolutionstudies.
 
Fig: 8.11 In-vitro drug release profile curve  for  formulation F1 
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 Fig 8.12 In-vitro  drug  release  profile  curve  for  formulation  F2 
 
Fig  8.13 In-vitro  drug  release  profile  curve of  formulation  F3 
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Fig 8.14 :In-vitro  drug  release  profile  of  formulation  F4 
 
 
 
                   Fig  8.15  : In-vitro  drug  release  profile  of  formulation  F5 
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                     Fig 8. 16   : In-vitro  drug  release  profile curve  for  formulation  F6 
 
 
 
                     Fig:8. 17: In-vitro  drug  release  profile  curve  of  formulation  F7 
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                            Figure 8.18 Invitro drug release profile of  Formulation F8 
 
Figure 8.19 In-vitro  drug  release  profile of  formulation F9 
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Figure 8.20: Invitro drug release profile of all nine Formulation (F1 to F9) 
 
Ibuprofen is a water insoluble drug; its release from the matrix is largely 
dependent on the polymer swelling, drug diffusion and matrix erosion. The 
concentration of polymer in the sustained   release layer was a key factor in 
controlling the drug release. Various sustained release formulations were formulated 
with HPMC K100M, ethyl cellulose,  polyvinyl pyrrolidone as binder and magnesium 
stearate as a  Lubricant. 
In vitro release studies of formulations F1, F2 and F3 prepared by HPMC 
K100M with concentrations of 10%, 20% & 30% respectively. The drug released 
from formulation F1 to F3 were found to be 93.7± 0.25, 92.9 ± 0.66, and 93.9 ± 
0.64% for Ibuprofen respectively. In vitro release studies of formulations F4, F5 and 
F6 prepared by ethyl cellulose with concentrations of 10%, 20%& 30% respectively. 
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The drug  released from formulation F4 to F6 were found to be 90.8 ± 0.07, 93.9 ± 
0.09, and 95.8 ± 0.26% for Ibuprofen respectively.  
In vitro release studies of formulations F7, F8 and F9 prepared by  wet 
granulation method. 
  The drug  released from formulation F7 to F9 were found to be 94.9 ± 0.15, 
95.6 ± 0.35, and 96.2 ± 0.65% for Ibuprofen respectively.  
The release rate of F9 was found to be higher when compared to other 
formulations this is due to increase in the concentration of polymer. 
 
The overall release rate of Ibuprofen from ethyl cellulose and HPMC K100M 
matrices are significantly higher than that from  matrices; were shown in Figure 7.20 . 
These results are indicating that  has higher drug retarding ability for long duration 
than ethyl cellulose and HPMC K100M.   
  
7.3.9. Data Analysis (Curve Fitting Analysis): 
Korsemeyer-Peppas model indicates that the release mechanism is not well 
known or more than one type of release phenomena could be involved. The ‘n’ value 
could be used to characterize different release mechanisms as: 
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Table 8.11:   Different drug release mechanisms of kinetic model 
 Release exponent (n) Drug Transport Mechanism 
0.5 Fickian diffusion  
0.45< n=0.89 Non- Fickian diffusion 
0.89 Case II transport 
Higher than 0.89 Super case II transport 
       
 
It ranges between 0.5 to 1, so it was concluded that the drug release occurred 
via non-fickian diffusion, which shows that the release from initially dry, hydrophilic 
glassy polymers that swell when added to water and become rubbery show anomalous 
diffusion as a result of the rearrangement of macro molecular chains 
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.Table 8.12: In-vitro Release Kinetic models for Ibuprofen sustained release 
Matrix tablets of formulations (F1 to F9) 
 
F. 
Code 
Zero 
order 
First 
order 
Higuchi Korsemeyer- Peppas Best fit 
model 
R2 R2 R2 R2 Slope(n) 
F1 0.989 0.965 0.862 0.992 1.268 Peppas 
F2 0.986 0.943 0.836 0.994 1.302     Peppas 
F3 0.984 0.932 0.815 0.991 1.376 Peppas 
F4 0.986 0.982 0.894 0.987 1.186 Peppas 
F5 0.983 0.955 0.890 0.989 1.279 Peppas 
F6 0.981 0.932 0.876 0.994 1.342 Peppas 
F7 0.986 0.971 0.831 0.991 1.197 Peppas 
F8 0.977 0.926 0.899 0.993 1.279 Peppas 
F9 0.964 0.989 0.893 0.995 1.262 Peppas 
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Figure 8.21: Best fit model (Peppas) of formulation F1 
 
 
Figure 8.22: Best fit model (Peppas) of formulation F2 
Ibuprofen sustained Release Tablets      RESULTS AND DISCUSSION                
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 122 
 
 
 
Figure 8.23: Best fit model (Peppas) of formulation F3 
 
 
 
Figure 8.24:  Best fit model (Peppas) of formulation F4 
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Figure 8.25:  Best fit model (Peppas) of formulation F5 
 
 
Figure 8.26: Best fit model (Peppas) of formulation F6 
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Figure 8.27: Best fit model (Peppas) of formulation F7 
 
 
Figure 8.28: Best fit model (Peppas) of formulation F8 
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Figure 8.29: Best fit model (Peppas) of formulation F9 
To know the kinetics of the best formulations, the release data was treated 
according to different models. Drug release data of tablets was fitted in peppas 
equation  and found release mechanism to be diffusion.  
           The results of dissolution data fitted to various drug release kinetic equations.  
Model was found to be the best fitted in all dissolution profile having higher 
correlation coefficient followed by the Peppas release equation. The kinetic values 
obtained from different formulations are tabulated in table 7.12. Optimized 
formulation F9 shows the Super case II transport Mechanism. 
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.4. Stability Study: 
After storage the formulation was analyzed for various physical parameters, 
results are showed in Table 7.13. 
 
Table 8.13: Stability study of best formulation F9. 
Characteristic Initial 1st Month 2nd Moth 3rd Month 
Hardness (kg/cm2)* 6.85±0.03 6.82±0.26 6.80±0.28 6.77±0.29 
Drug content (%)*   99.9±0.63 99.5±0.79  99.04±0.63 98.9±0.58 
In vitro drug release at 
10th hour* 
96.2±0.65 95.9±0.56 95.8±0.59 95.2±0.57 
        Appearance White No change No change No change 
*All the values are expressed as mean± SD, n=3 
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Figure 8.30: Comparisons of in vitro cumulative % drug release before and after 
                    stability period at accelerated temperature (40
0 
C ± 2
0 
C / 75%   RH±5%) 
                     after 3 months of stability studies. 
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9. SUMMARY AND CONCLUSION 
In present investigation an attempt has been made to design and develop 
Ibuprofen sustained release matrix tablets using HPMC K100M, and ethyl cellulose, 
as release retarding polymers. Ibuprofen is widely used as a centrally acting muscle 
relaxant; therefore have been selected to prepare sustained release dosage forms. 
An ideal matrix formulation prepared with different polymers and diluents 
concentrations should release its content in a sustained profile a reasonable length of 
time and preferably with Korsmeyer-peppas kinetic. 
The active pharmaceutical ingredient Ibuprofen was evaluated for its physical 
characteristics, analytical profiles and drug polymer compatibility study. The granules 
were prepared by wet granulation method. The prepared granules were evaluated for 
Angle of repose, Bulk density, Tapped density and Carr’s index. The results obtained 
were found to be satisfactory and within the specified limits.  
  After compression parameters like Thickness, Hardness, Weight variation, 
Friability, content uniformity and In-Vitro release studies were evaluated. 
Result of the present study demonstrated that hydrophilic polymers could be 
successfully employed for formulating sustained release matrix tablets of Ibuprofen. 
The investigated sustained release matrix tablet was capable of maintaining constant 
plasma concentration upto 10 hours. This can be expected to reduced the frequency of 
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administration and decrease the dose dependent side effects. The efficacy and safety 
of Ibuprofen tablet dosage form are expected to offer optimum therapeutic efficacy 
and improved patient compliance. 
In the present study the effect of types and concentration of polymer were 
studied on    In-Vitro drug release. It shows that increase in concentration of polymer 
results in the sustained drug release for 10 hours. The study has revealed that by 
increasing concentration of polymer, release rate of drug was retarded and results 
confirmed that the release rate from hydrophilic matrix tablets depends on type and 
concentration of polymer. 
        In present studies, matrix formulation containing HPMC and EC is probably 
showing release up to 96.2±0.65% within 10 hrs. 
According to stability study it was found that there was no significant change 
in hardness, drug content and in vitro dissolution of optimized formulation (F9). 
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10.FUTURE PROSPECTS 
In the present work the sustained release matrix tablets of Ibuprofen were 
formulated using hydrophilic polymers such as HPMC, ethyl cellulose and  by wet 
granulation method. In this work only physiochemical characterization, formulation 
and in-vitro evaluation matrix tablets of Ibuprofen was done. Along with in-vitro 
release study in-vivo release behavior of drug is also important. So in future in-vivo 
release study using different models are required to set the in-vitro in-vivo correlation 
which is necessary for development of successful formulation and also long term 
stability studies are necessary. 
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